Engineered viral capsids and methods of use
Patent Information
- Application Number
- JP2023552156
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-10
- Filing Date
- 2021-11-09
- Publication Date
- 2024-11-19
AI Technical Summary
Despite the clinical efficacy of adeno-associated virus (AAV) vectors in gene therapy, there is a need for improved cargo delivery to fully realize their potential, as existing vectors face limitations in transduction efficiency and tropism for specific cell types, particularly in ocular applications.
Modified AAV capsids containing exogenous polypeptide sequences in the VP domain, specifically formulated as X0-X1-X2-X1-X3-X1-X4, enhance transgene expression by up to 500-fold, improving tropism and transduction efficiency for retinal cells.
The modified AAV capsids demonstrate significantly enhanced transgene expression and tropism for retinal cells, effectively treating retinal diseases such as AMD and other ocular conditions with improved therapeutic efficacy.
Abstract
Description
[Technical Field]
[0001]
[0001] Cross reference This application claims the benefits of U.S. Provisional Patent Application No. 63 / 111,739, filed on November 10, 2020, which is incorporated herein by reference in its entirety.
[0002]
[0002] Sequence List This application includes a list of sequences, which has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy thereof, created on 8 November 2021, is named 59561701601_SL.txt and is 198,102 bytes in size. [Background technology]
[0003]
[0003] Adeno-associated virus (AAV) is a non-pathogenic parvovirus containing small single-stranded DNA with a non-enveloped protein capsid, which has attracted considerable attention as an efficient and safe vector for gene transfer. Recombinant AAV vectors have been or are currently used in 176 Phase I, II, and III clinical trials. AAV serotype 2 (AAV2) vectors have shown clinical efficacy in three human diseases: Leber's congenital amaurosis (LCA), aromatic L-amino acid decarboxylase deficiency (AADC), and congenital choroidal deficiency.
[0004]
[0004] Over the past decade, at least 12 additional AAV serotype vectors, some derived from non-human primates, have become available. The AAV1 vector has been well used in gene therapy for lipoprotein lipase deficiency, and the AAV8 vector has shown clinical efficacy in potential gene therapy for hemophilia B. More recently, the AAV5 vector has been reported to be effective in hemophilia A. The AAV9 vector has been well used in gene therapy for Pompe disease and has shown excellent efficacy in gene therapy for spinal muscular atrophy. The AAV1-LPL vector was approved as a drug named Alipogine neparbovec and marketed in Europe under the brand name Glybera in 2012. In 2017, the AAV2 vector expressing retinal pigment epithelium-specific 65kDa protein (RPE65) was approved by the Food and Drug Administration in the United States as the drug Boretigine neparbovec (Luxturna). Several additional Phase I and II clinical trials have been or are currently underway using the AAV1, AAV2, AAV3, AAV5, AAV6, AAV8, AAV9, and AAV10 vectors for potential gene therapy for various human diseases.
[0005]
[0005] Despite these remarkable achievements, it has become even clearer that the full potential of this technology will only be realized after the AAV vector has been modified for improved cargo delivery. [Overview of the Initiative] [Means for solving the problem]
[0006]
[0006] Compared to otherwise equivalent unmodified AAV capsids, modified adeno-associated virus (AAV) capsids comprising an exogenous polypeptide sequence in the VP domain of the AAV capsid are provided herein. In one embodiment, the exogenous polypeptide sequence comprises the sequence of formula 1: X0-X1-X2-X1-X3-X1-X1-X4-X5 (SEQ ID NO: 93), where X0 is valine (V), isoleucine (I), leucine (L), phenylalanine (F), tryptophan (W), tyrosine (Y), or methionine (M); X1 is alanine (A), asparagine (N), glutamine (Q), serine (S), threonine (T), glutamic acid (E), aspartic acid (D), lysine (K), arginine (R), or histidine (H); X2 is V, I, L, or M; X3 is E, S, or Q; X4 is K, R, E, or A; and optionally further comprises X5, where formula 1 is proline (P) or R. In one embodiment, formula 1 comprises X5, where X5 is proline (P) or R. In one embodiment, the capsid is serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, and any combination thereof. In one embodiment, the capsid comprises AAV2. In one embodiment, the capsid comprises at least two serotypes. In one embodiment, the at least two serotypes are selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV8, AAV9, AAV11, AAV12, and AAV13. In one embodiment, formula 1 includes LALG-X3-X1-X1-X4 (sequence number 94), LKLG-X3-X1-X1-X4 (sequence number 95), or VKLG-X3-X1-X1-X4 (sequence number 96). In one embodiment, formula 1 includes VKLG-X3-X1-X1-X4 (sequence number 96), in which case VKLG-X3-X1-X1-X4 (sequence number 96) includes VKLG-X3-X1-T-X4 (sequence number 97) or VKLG-X3-X1-X1-K (sequence number 98).In one embodiment, formula 1 includes LALG-X3-X1-X1-X4 (sequence number 94), in which case LALG-X3-X1-X1-X4 (sequence number 94) includes LALG-X3-X1-T-X4 (sequence number 99) or LALG-X3-X1-S-X4 (sequence number 100). In one embodiment, LALG-X3-X1-T-X4 (sequence number 99) includes a) LALG-X3-X1-TR (sequence number 101); b) LALG-X3-X1-TK (sequence number 102); c) LALG-X3-X1-TE (sequence number 103); or d) LALG-X3-X1-TA (sequence number 104). In one embodiment, LALG-X3-X1-S-X4 (sequence number 100) includes LALG-X3-X1-SK (sequence number 105). In one embodiment, formula 1 includes LKLG-X3-X1-X1-X4 (sequence number 95), in which case LKLG-X3-X1-X1-X4 (sequence number 95) includes LKLG-X3-X1-T-X4 (sequence number 106). In one embodiment, LKLG-X3-X1-T-X4 (sequence number 106) includes LKLG-X3-X1-TK (sequence number 107). In one embodiment, formula 1 includes a polypeptide sequence having at least 60%, 70%, 80%, 90%, 95%, 98%, or 99% identity with the sequences in Table 2. In one embodiment, formula 1 includes the polypeptide sequences in Table 2. In one embodiment, the VP domain of the AAV capsid is VP1. In one embodiment, the VP domain of the AAV capsid is VP2. In one embodiment, the VP domain of the AAV capsid is VP3. In one embodiment, the AAV capsid further comprises a mutation. In one embodiment, the mutation is located in the VP1 or VP2 region. In one embodiment, the mutation is located in the VP1 or VP3 region. In one embodiment, the mutation is located in the VP2 or VP3 region. In one embodiment, the mutation is located in the VP1, VP2, and VP3 regions. In one embodiment, the mutation is a point mutation, a missense mutation, a nonsense mutation, a deletion, a duplication, a frameshift, or a repeating extension. In one embodiment, the mutation is a point mutation.In some embodiments, a point mutation includes a conservative mutation. In some embodiments, a conservative mutation is selected from the group consisting of nonpolar aliphatic amino acid to nonpolar aliphatic amino acid, polar amino acid to polar amino acid, positively charged amino acid to positively charged amino acid, negatively charged amino acid to negatively charged amino acid, and aromatic amino acid to aromatic amino acid. In some embodiments, a point mutation includes a change from a charged amino acid residue to a polar or nonpolar amino acid residue. In some embodiments, the charged amino acid is positively charged. In some embodiments, the charged amino acid is negatively charged. In some embodiments, the mutation is at a residue in SEQ ID NO: 1. In some embodiments, the mutation is at a residue selected from the group consisting of 452, 453, 466, 467, 468, 471, 585, 586, 587, and 588 in SEQ ID NO: 1. In some embodiments, the point mutation is R to A at position 585 or 588 of SEQ ID NO: 1. In one embodiment, the AAV capsid further comprises at least a second exogenous polypeptide sequence in the VP1 domain of the AAV capsid. In one embodiment, the exogenous polypeptide sequence and the second exogenous polypeptide sequence are independently located in the loops of the AAV capsid. In one embodiment, the exogenous polypeptide sequence and the second exogenous polypeptide sequence are independently located in loops 3 and / or 4 of the VP1 domain of the AAV capsid.
[0007]
[0007] Provided herein are adeno-associated virus (AAV) vectors comprising (a) a modified capsid having an exogenous sequence in at least two loops of the VP domain compared to an otherwise equivalent AAV capsid sequence lacking an exogenous sequence; and (b) an adeno-associated virus (AAV) vector having, upon contact with a plurality of cells, an at least three-fold increase in the expression of the transgene after contact with the plurality of cells compared to contact with an otherwise equivalent AAV vector lacking (a). In one embodiment, the exogenous sequence encodes a polypeptide comprising formula 1:X0-X1-X2-X1-X3-X1-X1-X4 (SEQ ID NO: 108), where X0 is valine (V), isoleucine (I), leucine (L), phenylalanine (F), tryptophan (W), tyrosine (Y), or methionine (M); X1 is alanine (A), asparagine (N), glutamine (Q), serine (S), threonine (T), glutamic acid (E), aspartic acid (D), lysine (K), arginine (R), or histidine (H); X2 is V, I, L, or M; X3 is E, S, or Q; X4 is K, R, E, or A; and optionally further comprises X5, where formula 1 is proline (P) or R. In one embodiment, formula 1 comprises X5, where X5 is proline (P) or R. In one embodiment, the capsid is a capsid of serotypes AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, and any combination thereof. In one embodiment, the capsid comprises AAV2. In one embodiment, the capsid comprises at least two serotypes. In one embodiment, the at least two serotypes are AAV2 and AAV5, AAV2 and AAV6, AAV2 and AAV8, AAV2 and AAV9, AAV2 and AAV1, and AAV2 and AAV12. In one embodiment, formula 1 includes LALG-X3-X1-X1-X4 (sequence number 94), LKLG-X3-X1-X1-X4 (sequence number 95), or VKLG-X3-X1-X1-X4 (sequence number 96).In one embodiment, formula 1 includes VKLG-X3-X1-X1-X4 (sequence number 96), in which case VKLG-X3-X1-X1-X4 (sequence number 96) includes VKLG-X3-X1-T-X4 (sequence number 97) or VKLG-X3-X1-X1-K (sequence number 98). In one embodiment, formula 1 includes LALG-X3-X1-X1-X4 (sequence number 94), in which case LALG-X3-X1-X1-X4 (sequence number 94) includes LALG-X3-X1-T-X4 (sequence number 99) or LALG-X3-X1-S-X4 (sequence number 100). In one embodiment, LALG-X3-X1-T-X4 (sequence number 99) includes a) LALG-X3-X1-TR (sequence number 101); b) LALG-X3-X1-TK (sequence number 102); c) LALG-X3-X1-TE (sequence number 103); or d) LALG-X3-X1-TA (sequence number 104). In one embodiment, LALG-X3-X1-S-X4 (sequence number 100) includes LALG-X3-X1-SK (sequence number 105). In one embodiment, formula 1 includes LKLG-X3-X1-X1-X4 (sequence number 95), in which case LKLG-X3-X1-X1-X4 (sequence number 95) includes LKLG-X3-X1-T-X4 (sequence number 106). In one embodiment, LKLG-X3-X1-T-X4 (SEQ ID NO: 106) comprises LKLG-X3-X1-TK (SEQ ID NO: 107). In one embodiment, formula 1 comprises a polypeptide sequence having at least 60%, 70%, 80%, 90%, 95%, 98%, or 99% identity with the sequences in Table 2. In one embodiment, formula 1 comprises the polypeptide sequence in Table 2. In one embodiment, VP is VP1. In one embodiment, VP is VP2. In one embodiment, VP is VP3. In one embodiment, at least two loops are loops 3 and 4 of the VP1 domain. In one embodiment, the transgene encodes an ophthalmic therapeutic agent.In some embodiments, the ophthalmic therapeutic agent is effective in at least reducing the symptoms of retinal disease, treating retinal disease, or eliminating retinal disease. In some embodiments, the ophthalmic therapeutic agent is selected from the group consisting of antibodies or their bioactive fragments and biologics. In some embodiments, the therapeutic agent is a biologic, in which case the biologic comprises a polypeptide selected from lipoprotein lipase, retinoid isomerohydrolase RPE65, or complement factor H. In some embodiments, the therapeutic agent is an antibody or its bioactive fragment, in which case the antibody or its bioactive fragment is selected from anti-VEGF, anti-VEGFL, anti-thrombospondin 1, anti-CD47, anti-TNF-alpha, anti-CD20, anti-CD52, and anti-CD11a, anti-complement factor 5, and anti-complement factor 3. In one embodiment, retinal diseases include color blindness, neovascularization-related retinal disorders, such as age-related macular degeneration (AMD), exudative age-related macular degeneration (wAMD), geographic atrophy (GA), diabetic retinopathy (DR), diabetic macular edema (DME), glaucoma, Burdett-Beedle syndrome, Best's disease, congenital choroidal agenesis, Leber congenital amaranthoblastoma, Leber hereditary optic neuropathy (LHON), macular degeneration, polypoidal choroidal vasculopathy (PCV), retinitis pigmentosa, Refsum disease, Stargardt disease, Usher syndrome, X-linked retinoschisis (XLRS), hereditary retinal diseases (IRD), rod-cone dystrophy, cone-rod dystrophy, Oguchi disease, and Malattia. The following are selected from the group consisting of leventinese (familial dominant drusen), blue cone monochromatic color blindness, retinal vein occlusion (RVO), and uveitis macular edema (UMO). In one embodiment, the retinal disease is AMD. In one embodiment, the AMD is exudative AMD. In one embodiment, the AMD is atrophic AMD. In one embodiment, the vector further comprises a sequence encoding Rep. In one embodiment, Rep is modified, in which case the modification is in at least one of Rep78, Rep68, Rep52, or Rep40. In one embodiment, Rep is a different AAV serotype from the capsid. In one embodiment, VP is VP1. In one embodiment, VP is VP2.In one embodiment, VP is VP3. In one embodiment, the increase in expression includes at least a 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 200-fold, or 500-fold increase compared to contact with multiple cells and an otherwise equivalent AAV vector lacking (a). In one embodiment, the modified capsid contains at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to sequences including SEQ ID NOs. 28 to 47. In one embodiment, the vector contains the modified capsid of SEQ ID NO. 34.
[0008]
[0008] An engineered adeno-associated virus (AAV) virion comprising a modified adeno-associated virus (AAV) capsid is provided herein.
[0009]
[0009] Compositions comprising multiple AAV virions are also provided herein.
[0010]
[0010] Manipulated cells or manipulated virions produced by transfecting cells with vectors are also provided herein.
[0011]
[0011] Multiple adeno-associated virus (AAV) particles isolated from manipulated cells are provided herein.
[0012]
[0012] Compositions comprising adeno-associated virus particles in a unit dosage form are provided herein. In one embodiment, the composition is stored at low temperatures.
[0013]
[0013] A container is provided containing a) a modified adeno-associated virus (AAV) capsid; b) a vector; or c) an engineered virion. In one embodiment, the container is a vial, syringe, or needle. In one embodiment, the container is configured for ocular delivery.
[0014] A pharmaceutical composition comprising: a) a modified adeno-associated virus (AAV) capsid; b) a vector; or c) an engineered virion is provided. In certain embodiments, the pharmaceutical composition is in unit dosage form.
[0015] A method of generating engineered cells is also provided, the method comprising contacting a plurality of cells with a vector or an engineered virion.
[0016] A modified adeno-associated virus (AAV) capsid comprising an exogenous sequence of Table 2 is provided. In certain aspects, the capsid is of a serotype selected from the group consisting of AAV1, AAV2, AAV5, AAV8, AAV9, and combinations thereof.
[0017] A method of generating a modified adeno-associated virus (AAV) capsid, the method comprising introducing a polynucleotide encoding the sequence of Table 2 into a sequence encoding an AAV capsid, thereby generating a modified AAV capsid. In certain aspects, the AAV capsid is of a serotype selected from the group consisting of AAV1, AAV2, AAV5, AAV8, AAV9, and combinations thereof.
[0018] A method of treating a disease or condition in a subject in need thereof, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an adeno-associated virus (AAV) vector comprising a modified capsid comprising an exogenous polypeptide sequence in at least two loops of the VP domain, wherein the exogenous polypeptide sequence lacks an exogenous polypeptide sequence and is otherwise equivalent to the AAV capsid sequence, and the exogenous polypeptide sequence comprises the sequence of Table 2. In certain aspects, the AAV vector further comprises a sequence comprising a transgene.
[0019]
[0019] A method is provided for treating a disease or condition in a subject requiring treatment of the disease or condition, comprising the step of administering a therapeutically effective amount of a pharmaceutical composition comprising (a) a modified capsid having an exogenous sequence in at least two loops of the VP domain compared to an otherwise equivalent AAV capsid sequence lacking an exogenous sequence; and (b) an adeno-associated virus (AAV) vector having a transgene, wherein when the vector comes into contact with a plurality of cells, the transgene has at least three-fold increased expression in the plurality of cells after transfection compared to contact with the plurality of cells with an otherwise equivalent AAV vector lacking (a). In one embodiment, the increased expression includes an increase of at least five-fold, ten-fold, twenty-fold, fifty-fold, 100-fold, 200-fold, or 500-fold compared to contact with the plurality of cells with an otherwise equivalent AAV vector lacking (a).
[0020]
[0020] A method for treating a disease or condition in a subject requiring treatment of the disease or condition, comprising the step of administering a therapeutically effective amount of a pharmaceutical composition comprising an adeno-associated virus (AAV) vector comprising a modified capsid containing an exogenous polypeptide sequence in the VP domain of an AAV capsid, compared to otherwise equivalent unmodified AAV capsid, wherein the exogenous polypeptide sequence comprises the sequence of formula 1: X0-X1-X2-X1-X3-X1-X1-X4 (SEQ ID NO: 108), where X0 is valine (V), isoleucine (I), leucine ( A method is also provided in which formula 1 comprises X5, which is proline (P) or R, in one embodiment, formula 1 comprises X5, which is proline (P) or R. In one embodiment, formula 1 comprises X5, in this case X5 is proline (P) or R. In one embodiment, the capsid is serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, and any combination thereof. In one embodiment, the capsid contains AAV2. In one embodiment, the capsid contains at least two serotypes. In one embodiment, the at least two serotypes are selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV8, AAV9, AAV11, AAV12, and AAV13. In one embodiment, formula 1 contains LALG-X3-X1-X1-X4 (sequence number 94), LKLG-X3-X1-X1-X4 (sequence number 95), or VKLG-X3-X1-X1-X4 (sequence number 96).In one embodiment, formula 1 includes VKLG-X3-X1-X1-X4 (sequence number 96), in which case VKLG-X3-X1-X1-X4 (sequence number 96) includes VKLG-X3-X1-T-X4 (sequence number 97) or VKLG-X3-X1-X1-K (sequence number 98). In one embodiment, formula 1 includes LALG-X3-X1-X1-X4 (sequence number 94), in which case LALG-X3-X1-X1-X4 (sequence number 94) includes LALG-X3-X1-T-X4 (sequence number 99) or LALG-X3-X1-S-X4 (sequence number 100). In one embodiment, LALG-X3-X1-T-X4 (sequence number 99) includes a) LALG-X3-X1-TR (sequence number 101); b) LALG-X3-X1-TK (sequence number 102); c) LALG-X3-X1-TE (sequence number 103); or d) LALG-X3-X1-TA (sequence number 104). In one embodiment, LALG-X3-X1-S-X4 (sequence number 100) includes LALG-X3-X1-SK (sequence number 105). In one embodiment, formula 1 includes LKLG-X3-X1-X1-X4 (sequence number 95), in which case LKLG-X3-X1-X1-X4 (sequence number 95) includes LKLG-X3-X1-T-X4 (sequence number 106). In one embodiment, LKLG-X3-X1-T-X4 (SEQ ID NO: 106) includes LKLG-X3-X1-TK (SEQ ID NO: 107). In one embodiment, Formula 1 includes a polypeptide sequence having at least 60%, 70%, 80%, 90%, 95%, 98%, or 99% identity with the sequences in Table 2. In one embodiment, Formula 1 includes the polypeptide sequences in Table 2. In one embodiment, the administration step is carried out by intravitreous injection, subretinal injection, microinjection, or superocular injection. In one embodiment, the administration step is carried out by intravitreous injection. In one embodiment, the disease or condition is an ocular disease or condition. In one embodiment, the disease or condition is a non-ocular disease or condition. In one embodiment, the ocular disease or condition is a retinal disease or condition.In one embodiment, eye diseases or conditions include color blindness, neovascularization-associated retinal disorders such as age-related macular degeneration (AMD), exudative age-related macular degeneration (wAMD), geographic atrophy (GA), diabetic retinopathy (DR), diabetic macular edema (DME), glaucoma, Burdett-Beedle syndrome, Best's disease, congenital choroidal agenesis, Leber congenital amaranthoblastoma, Leber hereditary optic neuropathy (LHON), macular degeneration, polypoidal choroidal vasculopathy (PCV), retinitis pigmentosa, Refsum disease, Stargardt disease, Usher syndrome, X-linked retinoschisis (XLRS), hereditary retinal diseases (IRD), rod-cone dystrophy, cone-rod dystrophy, Oguchi disease, and Malattia. The therapeutic agent is selected from the group consisting of leventinese (familial dominant drusen), blue cone monochromatic color blindness, retinal vein occlusion (RVO), and uveitis macular edema (UMO). In one embodiment, the ocular disease or condition is AMD. In one embodiment, AMD is exudative AMD. In one embodiment, AMD is atrophic AMD. In one embodiment, the administration step is sufficient to at least reduce the symptoms of the disease or condition, treat the disease or condition, and / or eliminate the disease or condition. In one embodiment, the vector further comprises a transgene encoding a therapeutic polypeptide. In one embodiment, the therapeutic agent is selected from the group consisting of antibodies or bioactive fragments thereof or biologics. In one embodiment, the therapeutic agent is a biologic, in which case the biologic comprises a polypeptide selected from lipoprotein lipase, retinoid isomerohydrolase RPE65, and complement factor H. In one embodiment, the therapeutic agent is an antibody or a bioactive fragment thereof, in which case the antibody or bioactive fragment is selected from anti-VEGF, anti-VEGFL, anti-thrombospondin 1, anti-CD47, anti-TNF-alpha, anti-CD20, anti-CD52, and anti-CD11a. In one embodiment, prior to the administration step, the subject undergoes genetic testing. In one embodiment, genetic testing detects mutations in genes selected from RPE65, CRB1, AIPL1, CFH, or RPGRIP. In one embodiment, the administration step is approximately 1.0 × 10⁻⁶. 9 vg, 1.0 × 1010 , 1.0×10 11 vg, 3.0×10 11 vg, 6×10 11 vg, 8.0×10 11 vg, 1.0×10 12 vg, 1.0×10 13 vg, 1.0×10 14 vg, or 1.0×10 15 vg, and includes the step of delivering a dosage of the vector. In certain embodiments, the administering step is repeated. In certain embodiments, the administering step is performed twice a day, every other day, twice a week, every other month, every three months, once a month, every other month, every six months, annually, or twice a year. In certain embodiments, the method further includes the step of administering a secondary therapy. In certain embodiments, VP includes VP1. In certain embodiments, VP includes VP2. In certain embodiments, VP includes VP3.
[0021]
[0021] Incorporation by reference All publications, patents, and patent applications mentioned in this specification are hereby incorporated by reference as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
[0022]
[0022] The novel features of the present disclosure are set forth with the details in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description, which shows exemplary embodiments in which the principles of the present disclosure are utilized, and the accompanying drawings, which are as follows:
Brief Description of the Drawings
[0023] [Figure 1]
[0023] It is a diagram showing the structural modeling of AAV2 capsid and its variants. The left panel shows the 60mer AAV2 capsid colored in gray, with the reference monomer colored in dark gray and the insertions on each monomer shown in different colors. The right panel shows the monomer VP of AAV2 having peptide insertions in loop 3 and loop 4. [Figure 2]
[0024] This figure shows SDS-PAGE indicating the purity of the AAV2 vector. M, protein ladder; lanes 1-10, AMI051-AMI057, V467, 7m8 control vector, and wild-type (WT) control AAV2. Each lane was loaded with 1e+11vg. [Figure 3A]
[0025] This figure shows the transduction efficiency of modified AAV2 capsid variants in human cell lines. HEK293 and ARPE-19 cells were transduced with the wild-type (wt., AAV2-V104) and modified capsid variants (AAV2-V466, AAV2-V467, and AAV2-V471) of the AAV2-CMV-GFP vector at an MOI of 1e+5vg / cell. [Figure 3B] This figure shows the transduction efficiency of modified AAV2 capsid variants in human cell lines. HEK293 transgene expression was analyzed by fluorescence microscopy 72 hours after transduction. [Figure 3C] Figures 3C and 3D show ELISA measurements of VEGF-Trap expression in human HEK293 cells (Figure 3C) and human ARPE-19 cells (Figure 3D) transduced with the modified AAVs described herein: modified AAV1, which includes an insertion of the LALGQTTKPA exogenous polypeptide (SEQ ID NO: 14) after amino acid residue 588 (asparagine, N); modified AAV2, which includes an S588 insertion of the LALGQTTKPA exogenous polypeptide (SEQ ID NO: 14) after amino acid residue 588 (serine, S); and modified AAV6, which includes an S588 insertion of the LALGQTTKPA exogenous polypeptide (SEQ ID NO: 14) after amino acid residue 588 (serine, S). [Figure 3D]Figures 3C and 3D show ELISA measurements of VEGF-Trap expression in human HEK293 cells (Figure 3C) and human ARPE-19 cells (Figure 3D) transduced with the modified AAVs described herein: modified AAV1, which includes an insertion of the LALGQTTKPA exogenous polypeptide (SEQ ID NO: 14) after amino acid residue 588 (asparagine, N); modified AAV2, which includes an S588 insertion of the LALGQTTKPA exogenous polypeptide (SEQ ID NO: 14) after amino acid residue 588 (serine, S); and modified AAV6, which includes an S588 insertion of the LALGQTTKPA exogenous polypeptide (SEQ ID NO: 14) after amino acid residue 588 (serine, S). [Figure 4]
[0026] This figure shows representative flat-mount images of GFP expression on day 28. GFP expression was examined on mouse retinal flat mounts after whole-mount staining. GFP expression in groups 2 and 3 was significantly more robust, and therefore, images were acquired at lower gain settings so that intracellular GFP could be identified. [Figure 5]
[0027] This figure shows representative images from immunohistochemical analysis of eyes on day 28. Three different antibody cocktails were used to evaluate the localization of expressed GFP. GFP was abundant in the eyes of group 3, so the primary and secondary antibodies did not completely capture it, resulting in the detection of endogenous GFP in addition to immunolabeled GFP (group 3, column 1). [Figure 6]
[0028] This is a graphical representation of GFP expression across all three antibody cocktails and eyes that were imaged. GFP expression was scored across all retinal layers and outer retinal layers, as well as across all antibody cocktails used, for the investigation of ocular expression across all eyes; each eye is represented by one row. Gray cells indicate locations where positive GFP expression was observed; white cells indicate the absence of GFP expression. Abbreviations: GCL / ILM - Ganglion cell layer / internal limiting membrane; IPL - Inner plexiform layer; INL - Inner granular layer; OPL - Outer plexiform layer; ONL - Outer granular layer; IS - Inner segment; OS - Outer segment; RPE - Retinal pigment epithelium; C - Choroid; S - Sclera; M - Muscle; ONH - Optic disc. [Figure 7]
[0029] The figure shows in vivo fundus imaging and immunohistochemical (IHC) staining of the eye, in which wild-type (wt) AAV2 was administered intravitreously (IVT) to the mouse eye. Wt AAV2-GFP did not achieve sufficient GFP expression, as shown in both fundus imaging and IHC sections. The figure discloses Sequence ID No. 133. [Figure 8]
[0030] The figure shows in vivo fundus imaging and IHC staining of the eye, in which a modified AAV2 (AAV2-AMI053-GFP, which includes a modified AAV2 having LKLGQTTKPA (SEQ ID NO: 13) inserted after amino acid residue 587) as described herein was administered to the eye of a mouse via the IVT pathway. The modified AAV2 showed GFP expression in fundus imaging and IHC sections, and the GFP signal was detected in multiple layers of cells. The figure discloses SEQ ID NO: 116. [Figure 9]
[0031] The figure shows in vivo fundus imaging and IHC staining of the eye, in which a modified AAV2 (AAV2-AMI054-GFP, which includes a modified AAV2 having LALGQTTKPA (SEQ ID NO: 14) inserted after amino acid residue 587) as described herein was administered to the eye of a mouse via the IVT pathway. The modified AAV2 showed GFP expression in fundus imaging and IHC sections, and the GFP signal was detected in multiple layers of cells. The figure discloses SEQ ID NO: 117. [Figure 10]
[0032] The figure shows in vivo fundus imaging and IHC staining of the eye, in which a modified AAV2 (AAV2-V466-GFP, including a modified AAV2 with LALGETTRPA (SEQ ID NO: 6) inserted after amino acid residue 453) as described herein was administered to the eye of a mouse via the IVT pathway. The modified AAV2 showed GFP expression in fundus imaging and IHC sections, and the GFP signal was detected in multiple layers of cells. The figure discloses SEQ ID NO: 110. [Figure 11]
[0033] This figure shows the AAV retinal transduction index (ARCTI), which indicates AAV transduction in different ocular fiber layers of eyes transduced with either wild-type (Wt) or a modified AAV as described herein. [Figure 12]
[0034] This figure shows the results of a mouse laser-induced choroidal neovascularization (LCNV) study, in which modified AAVs were administered to mice prior to LCNV. AAV1, AAV2, or AAV6 were modified by inserting LALGQTTKPA (SEQ ID NO: 14) into the VP1 capsid and have aflibercept (VEGF-Trap) as a transgene for delivery to the mouse eye. Modified AAV1 (Group 5, AAV1.N54-aflibercept) contains LALGQTTKPA (SEQ ID NO: 14) inserted after amino acid residue S588 of the VP1 capsid. AAV2 (Group 3, AAV2.N54-aflibercept) contains LALGQTTKPA (SEQ ID NO: 14) inserted after amino acid residue N587 of the VP1 capsid. AAV6 (Group 4, AAV6.N54-aflibercept) contains LALGQTTKPA (SEQ ID NO: 14) inserted after the S588 amino acid residue of the VP1 capsid. [Figure 13]
[0035] Figure 13A shows the area of choroidal neovascularization in the eye from the LCNV study in Figure 12. ΔAflibercept is a sham control in which AAV containing disruption in the open reading frame was administered to the eye of mice. Compared to the medium group, all three modified AAV groups showed a significant reduction in the area of choroidal neovascularization in the eye (AAV6.N54-aflibercept, p<0.001; AAV1.N54-aflibercept, p<0.01; and AAV2.N54-aflibercept, p<0.05). Figure 13B shows that the group administered with AAV6.N54-aflibercept continued to show a significant reduction in the area of choroidal neovascularization in the eye (AAV6.N54-aflibercept, p<0.05). [Figure 14]
[0036] Figure 12 shows the concentrations of aflibercept in eye (left and center panels) and serum (right panel) samples obtained from LCNV study mice. [Figure 15]
[0037] Figure 12 shows the fluorescein angiography (FA) analysis of the protective effect of retinal aflibercept against LCNV-induced retinal damage in mice. The correlation between aflibercept concentration in the optic cup and retinal damage caused by laser treatment was inverse. [Figure 16]
[0038] This figure shows fundus images from day 21. The posterior portion of the eye was imaged in both the color and cobalt blue channels. Imaging acquisition settings for GFP expression were calibrated in group 6 animals, and levels were maintained consistently throughout this study. [Figure 17]
[0039] This figure shows representative images from immunohistochemical analysis of the eye on day 28. Frozen sections (14 μm) were evaluated for the localization of GFP, RPE65, phalloidin, and DAPI. The merged image is shown on the left, and the GFP channel pullout is shown on the right. [Figure 18]
[0040] This figure shows representative images from immunohistochemical analysis of eyes at day 28 using confocal microscopy. Frozen sections (14 μm) were evaluated for localization of GFP, RPE65, phalloidin, and DAPI. Merged images are shown on the left, and GFP is shown on the right. [Figure 19A]
[0041] This figure shows the intravitreous delivery of AAV2.AMI054-GFP (modified AAV2 including the insertion of LALGQTTKPA (SEQ ID NO: 14)) in the eye of a pig. IHC staining showed GFP fluorescence in the retinal layer. [Figure 19B] This figure shows GFP expression in each retinal layer of an eye administered with AAV2.AMI054-GFP. [Figure 20]
[0042] This figure compares GFP expression in the retinas of pigs administered with AAV2.AMI054-GFP and those administered with AAV2.7M8-GFP (control). In contrast to the retinas transduced with AAV2.7M8-GFP, the retinas transduced with AAV2.AMI054-GFP showed GFP expression in all retinal layers. GFP fluorescence in the AAV2.AMI054-GFP transduced retinas was twice as strong as that in the AAV2.7M8-GFP transduced retinas. [Modes for carrying out the invention]
[0024]
[0043] The following description and examples illustrate embodiments of the present invention in detail. It should be understood that the present invention is not limited to the specific embodiments described herein and can therefore be modified. Those skilled in the art will recognize that various modifications and variations of the present invention exist and are included within the scope of the invention.
[0025]
[0044] definition The terms “AAV,” “AAV construct,” “recombinant AAV,” or “AAV” refer to any known serotype of adeno-associated virus, e.g., AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, or scAAV, rh10, chimeric or hybrid AAV, or any combination, derivative, or variant thereof. AAVs are small, non-enveloped, single-stranded DNA viruses. They are non-pathogenic parvoviruses and may require helper viruses, e.g., adenoviruses, herpes simplex viruses, vaccinia viruses, and CMV, for replication. Wild-type AAVs are common in the general population and are not associated with any known pathology. A hybrid AAV is an AAV that contains a capsid protein from one AAV serotype and genomic material from another AAV serotype. A chimeric AAV contains gene sequences and / or protein sequences derived from two or more AAV serotypes and may include mutations made to the gene sequences of those two or more AAV serotypes. An exemplary chimeric AAV may contain a chimeric AAV capsid, for example, a capsid protein having one or more amino acid regions derived from two or more AAV serotypes. An AAV variant is an AAV that contains one or more amino acid mutations in its genome or protein compared to its parent AAV, for example, an AAV that contains one or more amino acid mutations in its capsid protein compared to its parent AAV. As used herein, AAV encompasses avian AAV, bovine AAV, canine AAV, equine AAV, primate AAV, non-primate AAV, and sheep AAV, where primate AAV means AAV that infects non-primate animals, and non-primate AAV means AAV that infects non-primate animals, such as avian AAV that infects birds. In some cases, wild-type AAV contains rep and cap genes, where the rep gene is required for viral replication and the cap gene is required for the synthesis of the capsid protein. As used herein, the terms “recombinant AAV” and “rAAV” are interchangeable.
[0026]
[0045] The terms “recombinant AAV vector” or “AAV vector” or “AAV vector” mean a vector derived from any of the AAV serotypes mentioned above. In some cases, an AAV vector may include one or more AAV wild-type genes, all or part of which have been removed, such as rep and / or cap genes, but also include functional elements necessary for packaging and using the AAV virus for gene therapy. For example, open reading frames or functional reverse-terminal repeat sequences or ITR sequences adjacent to cloned exogenous sequences are known to be important for the replication and packaging of AAV virions, but ITR sequences can be modified from wild-type nucleotide sequences, for example, by nucleotide insertions, deletions, or substitutions, thereby making the AAV suitable for use in the embodiments described herein, such as gene therapy or gene delivery systems. In some embodiments, self-complementary vectors (sc), such as self-complementary AAV vectors, can be used, which can avoid the requirement for viral second-strand DNA synthesis and may result in a higher rate of transgene protein expression, as described in Wu, Hum Gene Ther. 2007, 18(2):171-82, incorporated herein by reference. In some embodiments, AAV vectors can be generated to allow for the selection of optimal serotype, promoter, and transgene. In some cases, the vector may be a target vector or a modified vector that selectively binds to or infects immune cells.
[0027]
[0046] The term “AAV virion” means a viral particle comprising a capsid containing at least one AAV capsid protein encasing an AAV vector as described herein, in which case the vector may further comprise, in some embodiments, a non-homologous polynucleotide sequence or a transgene. The virion may be an engineered virion.
[0028]
[0047] As used herein, the term "about" and its grammatical equivalents in relation to reference values and their grammatical equivalents may encompass values within a range of plus or minus 10% from the reference value. For example, the quantity "about 10" encompasses the quantities from 9 to 11. In relation to reference values, the term "about" may also include values within a range of plus or minus 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% from the reference value.
[0029]
[0048] The terms “subject,” “host,” “individual,” and “patient” are used interchangeably herein to mean an animal, typically a mammal. Any suitable mammal may be administered with the compositions described herein (e.g., engineered guide RNA, etc.) or treated in the manner described herein. The subject may be a vertebrate or an invertebrate. The subject may be a laboratory animal. Non-limiting examples of mammals include humans, non-human primates (e.g., apes, gibbons, chimpanzees, orangutans, monkeys, macaques, etc.), livestock (e.g., dogs and cats), farm animals (e.g., horses, cattle, goats, sheep, pigs), and laboratory animals (e.g., mice, rats, rabbits, guinea pigs). In some embodiments, the mammal is a human. The mammal may be of any age or any developmental stage (e.g., adult, adolescent, child, infant, or intrauterine mammal). The mammal may be male or female. In some embodiments, the subject is a human. The subject may be a patient. The subject may suffer from a disease. The subject may exhibit symptoms of a disease. The subject may not exhibit symptoms of a disease but still have the disease. The subject may be under the medical care of a caregiver (for example, the subject may be hospitalized and treated by a doctor).
[0030]
[0049] The terms “protein,” “peptide,” and “polypeptide” are used interchangeably and, in their broadest sense, mean compounds of two or more subunit amino acids, amino acid analogs, or peptidomimetics. This term also encompasses amino acid polymers that have been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other operation, such as conjugation with a labeling component. As used herein, the term “amino acid” means any natural and / or unnatural or synthetic amino acid, such as glycine and both D- and L-optical isomers, as well as amino acid analogs, and peptidomimetics, etc. Subunits may be linked by peptide bonds. In another embodiment, subunits may be linked by other bonds, such as esters, ethers, etc. A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that may make up a protein sequence or peptide sequence. As used herein, the term “amino acid” means any natural and / or unnatural or synthetic amino acid, such as glycine and both D and L optical isomers, amino acid analogs, and peptidomimetics. As used herein, the term “fusion protein” means a protein composed of domains derived from two or more naturally occurring or recombinant proteins, in which case each domain generally performs a different function. In this regard, the term “linker” optionally means a protein fragment used to link these domains together in order to preserve the conformation of the fusion protein domains and / or to prevent undesirable interactions between the fusion protein domains that may interfere with their respective functions.
[0031]
[0050] A polynucleotide or polypeptide has a certain percentage of "sequence identity" with respect to another polynucleotide or polypeptide, meaning that when aligned, the percentage of bases or amino acids will be the same when comparing the two sequences. Sequence similarity can be determined in several different ways. To determine sequence identity, sequences can be aligned using methods and computer programs, such as BLAST, available on the World Wide Web at ncbi.nlm.nih.gov / BLAST / . Another alignment algorithm is FASTA, available in a package from Genetics Computing Group (GCG) (Madison, Wisconsin, USA), a wholly owned subsidiary of Oxford Molecular Group, Inc. Other techniques for alignment are described in the methods in Enzymology, vol. 266: Computer Methods for Macromolecular Sequence Analysis (1996), ed. Doolittle, Academic Press, Inc., a division of Harcourt Brace & Co., San Diego, Calif., USA. Of particular interest are alignment programs that allow for sequence gaps. Smith-Waterman is one such algorithm that allows for gaps in sequence alignment. See Meth. Mol. Biol. 70: 173~187 (1997). In addition, GAP programs using Needleman and Wunsch alignment can also be used to align sequences. See J. Mol. Biol. 48: 443~453 (1970).
[0032]
[0051] overview Modified adeno-associated virus (AAV) capsid-containing compositions and methods of use thereof are provided herein. Modified AAV capsids may contain exogenous sequences compared to otherwise equivalent unmodified AAV capsids. Exogenous sequences may mean exogenous polypeptide sequences. AAV capsids can be modified to confer them, and any compositions and / or methods utilizing them may improve functionality, thereby resulting in better therapeutic agents, particularly for ophthalmic use.
[0033]
[0052] The AAV wild-type (WT) genome contains at least three genes: rep, cap, and X. The X gene, first described in 1999, is located at the 3' end of the genome (nucleotides 3929-4393 of AAV2) and is thought to encode a protein with a supportive function in genome replication. Further information on rep and cap is available. The rep gene is located in the first half of the AAV WT genome and encodes a family of non-structural proteins (Rep proteins) necessary for viral transcriptional regulation and replication, as well as for packaging the viral genome into a newly produced, pre-assembled capsid. The second half of the AAV genome contains the cap gene, which encodes viral proteins (VPs) VP1, VP2, and VP3, as well as assembly-activating proteins (AAPs). The transcription of all VPs, which are capsid monomers, is regulated by a single promoter (p40 in the case of AAV2), resulting in a single mRNA. Splicing (VP1) and an unusual translation start codon (VP2) are the reasons for the approximately 10-fold lower presence of VP1 and VP2 compared to VP3. As expected, when encoded by a single gene, AAV VPs share most of their amino acids. In detail, the entire VP3 sequence is contained within VP2 and VP1 ("common VP3 region"), and VP2 and VP1 also share approximately 65 amino acids ("common VP1 / VP2 region"). Only VP1 contains a unique sequence at its N-terminus (approximately 138 amino acids, VP1 unique). AAP was identified in 2010 as a 23kD protein encoded in an alternative cap ORF. It is used to stabilize newly produced VP proteins and to transport them from the cytoplasm into the cell nucleus. Interestingly, AAV serotypes 1-3, 6-9, and rh10 do not produce capsids in the absence of AAP, but the production of low-molecular-weight but detectable capsids has been reported in AAV4 and AAV5.
[0034]
[0053] In some embodiments, AAV may include modifications. A modification may be a modification of rep, cap, and / or X encoding the polypeptide sequence of AAV. In some cases, a modification may be a modification of the cap polypeptide. The cap polypeptide may be modified in any one of the VP domains, e.g., VP1, VP2, and / or VP3. In some cases, VP1 is modified. In some cases, VP2 is modified. In some cases, VP3 is modified. In some embodiments, two or all of the VP domains may be modified. In some cases, VP1 and VP2 are modified. In some cases, VP1 and VP3 are modified. Furthermore, VP2 and VP3 may be modified, or VP1, VP2, and VP3 are modified. Other combinations are conceivable, e.g., Rep and Cap, Cap and X, Rep and X, and / or modifications in Rep, Cap, and X. Any combination of domains may be modified, for example, in combination with any one of the aforementioned VP modifications in conjunction with a Rep and / or X modification. In some cases, Rep and VP1 and / or VP2 are modified. In some embodiments, the subject Rep is modified. Rep modifications may include modifications provided herein and may be present in at least one of Rep78, Rep68, Rep52, or Rep40. In some cases, Rep is a different AAV serotype from the subject capsid.
[0035]
[0054] In some cases, the modification is a modification of the AAV capsid. The AAV serotype capsid is assembled from 60 VP monomers, with approximately 50 copies of VP3, 5 copies of VP2, and 5 copies of VP1. The topologically protruding capsid surface structure consists of pores or "channel-like structures" on each five-fold symmetry axis, depressions on each two-fold symmetry axis, and three protrusions surrounding each three-fold symmetry axis. The pores allow for exchange between the inside and outside of the capsid. The depressions, which are more precise floors on each two-fold axis, are the thinnest parts of the viral capsid. The protrusions around the three-fold axes harbor five of the nine so-called variable regions (VRs). In detail, VR-IV, -V, and -VIII form loops (loops 1-4) at the tips of the protrusions, while VR-VI and -VII are found in their bases. VRs differ among serotypes, causing serotype-specific modifications in antibody-receptor binding. Due to their exposed location and function in receptor binding, protruding VR-forming loops are ideal locations for capsid modifications aimed at redirecting or expanding AAV tropism (cell surface targeting). Redirected tropism (vector retargeting) combines, for example, site-directed mutagenesis, cleaving innate receptor binding with the insertion of ligands that modulate transduction by novel non-innate AAV receptors, while AAV vectors with expanded tropism gain the ability to transduce cells by extra receptors while maintaining their innate receptor binding ability.
[0036]
[0055] In some embodiments, modification of the AAV capsid may mean the insertion of an exogenous polypeptide sequence. In other embodiments, modification may mean a deletion in the polypeptide sequence. Modification may also mean modification of at least one canonical or non-canonical amino acid residue in the polypeptide sequence.
[0037]
[0056] An insertion may involve inserting at least one exogenous amino acid residue into the sequence encoding the AAV capsid. The amino acid may be a canonical or non-canonical amino acid. Any number of amino acid residues can be inserted. In some cases, the insertion site may be the GH loop or loop IV of the AAV capsid protein, e.g., a solvent-accessible portion of the GH loop or loop IV of the AAV capsid protein. For the GH loop / loop IV of the AAV capsid, see van Vliet et al. (2006) Mol. Ther. 14:809; Padron et al. (2005) J. Virol. 79:5047; and Shen et al. (2007) Mol. Ther. 15:1955.
[0038]
[0057] In some cases, the modification involves the insertion of an exogenous polypeptide sequence containing the sequence of formula 1: X0-X1-X2-X1-X3-X1-X1-X4 (sequence number 108).
[0039]
[0058] In some cases, X0 is valine (V), isoleucine (I), leucine (L), phenylalanine (F), tryptophan (W), tyrosine (Y), or methionine (M). In some cases, X1 is alanine (A), asparagine (N), glutamine (Q), serine (S), threonine (T), glutamic acid (E), aspartic acid (D), lysine (K), arginine (R), or histidine (H). In some cases, X2 is V, I, L, or M, in which case X3 is E, S, or Q. In some cases, X4 is K, R, E, or A. In some cases, formula 1 further includes X5, which may be proline (P) or R.
[0040]
[0059] In some cases, formula 1 comprises LALG-X3-X1-X1-X4 (sequence number 94), LKLG-X3-X1-X1-X4 (sequence number 95), or VKLG-X3-X1-X1-X4 (sequence number 96). In some cases, formula 1 comprises VKLG-X3-X1-X1-X4 (sequence number 96). In some cases, the exogenous polypeptide is VKLG-X3-X1-T-X4 (sequence number 97) and / or VKLG-X3-X1-X1-K (sequence number 98). In some cases, the exogenous polypeptide comprises LALG-X3-X1-X1-X4 (sequence number 94). In some cases, the exogenous polypeptide comprises LALG-X3-X1-T-X4 (sequence number 99) and / or LALG-X3-X1-S-X4 (sequence number 100). In some cases, the exogenous polypeptide includes LALG-X3-X1-TR (SEQ ID NO: 101), LALG-X3-X1-TK (SEQ ID NO: 102), LALG-X3-X1-TE (SEQ ID NO: 103), and / or LALG-X3-X1-TA (SEQ ID NO: 104). In some cases, the exogenous polypeptide includes LALG-X3-X1-SK (SEQ ID NO: 105). In some cases, the exogenous polypeptide includes LKLG-X3-X1-X1-X4 (SEQ ID NO: 95). In some cases, the exogenous polypeptide includes LKLG-X3-X1-T-X4 (SEQ ID NO: 106). In some cases, the exogenous polypeptide includes LKLG-X3-X1-TK (SEQ ID NO: 107).
[0041]
[0060] In some cases, the exogenous polypeptide contains the sequence of formula 1. In some cases, the sequence of formula 1 contains a polypeptide sequence that has at least 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, or up to about 100% identity with the sequences in Table 2. In some cases, the exogenous polypeptide is one of those in Table 2 with 0 to 2 modifications to residues. In some cases, the exogenous polypeptide contains a sequence that has at least 90%, 95%, 97%, or up to about 99% sequence identity with SEQ ID NO: 13. In some cases, the exogenous polypeptide contains SEQ ID NO: 13 or a polypeptide with 0 to 2 substitutions to SEQ ID NO: 13.
[0042]
[0061] In some cases, at least two exogenous polypeptides, such as those described by Formula 1, are inserted into the AAV capsid sequence provided herein. These at least two exogenous polypeptides may be inserted at the same or different positions. In one embodiment, any one of the exogenous polypeptide sequences provided in Table 2 may be inserted into an unmodified AAV capsid sequence, such as the wild-type sequence provided in Table 1, to generate a modified AAV capsid.
[0043]
[0062] Similarly, a deletion may involve removing at least one amino acid residue in the sequence encoding the AAV capsid. Any number of amino acids can be removed.
[0044]
[0063] In some cases, at least, or up to: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or up to approximately 50 exogenous amino acid residues can be inserted and / or removed in the polypeptide sequence encoding the AAV capsid. In some cases, at least, or up to: 1–5, 5–10, 10–15, 15–20 exogenous amino acid residues, or combinations thereof, can be inserted and / or removed in the polypeptide sequence encoding the AAV capsid. In some cases, approximately 5, or up to approximately 5 to approximately 11, amino acids are inserted into the insertion site in the GH loop or loop IV of the capsid protein, compared to the corresponding unmodified AAV capsid protein. For example, the insertion site may be between amino acids 587 and 588 of AAV2, or at a corresponding position in the capsid subunit of another AAV serotype. It should be noted that the insertion site 587–588 is based on the AAV2 capsid protein. Approximately 5 to approximately 11 amino acids can be inserted into the corresponding site in AAV serotypes other than AAV2 (e.g., AAV5, AAV6, AAV8, AAV9, etc.).
[0045]
[0064] In some embodiments, the insertion site is a single insertion site between two adjacent amino acids located between amino acids 570–614 of VP1 of any AAV serotype, for example, the insertion site is between two adjacent amino acids located between amino acids 570–610, 580–600, 570–575, 575–580, 580–585, 585–590, 590–600, or 600–614 of VP1 of any AAV serotype or variant. For example, the insertion site may be between amino acids 580–581, 581–582, 583–584, 584–585, 585–586, 586–587, 587–588, 588–589, or 589–590. The insertion site may be between amino acids 575 and 576, 576 and 577, 577 and 578, 578 and 579, or 579 and 580. The insertion site may be between amino acids 590 and 591, 591 and 592, 592 and 593, 593 and 594, 594 and 595, 595 and 596, 596 and 597, 597 and 598, 598 and 599, or 599 and 600.
[0046]
[0065] In some embodiments, the insertion site may be between amino acids 587 and 588 of AAV2, between amino acids 590 and 591 of AAV1, between amino acids 575 and 576 of AAV5, between amino acids 590 and 591 of AAV6, between amino acids 589 and 590 of AAV7, between amino acids 590 and 591 of AAV8, between amino acids 588 and 589 of AAV9, or between amino acids 588 and 589 of AAV10.
[0047]
[0066] As another example, the insertion site may be between amino acids 450 and 460 of the AAV capsid protein, as shown in Table 1. For example, the insertion site may be amino acid 453 of AAV2 (e.g., directly adjacent to the N-terminus), amino acid 454 of AAV1, amino acid 454 of AAV6, amino acid 456 of AAV7, amino acid 456 of AAV8, amino acid 454 of AAV9, or amino acid 456 of AAV10.
[0048]
[0067] In some embodiments, the subject capsid protein includes a GH loop containing an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or 100% amino acid sequence identity with the amino acid sequences described in Table 1. Those skilled in the art will know, based on comparison with the amino acid sequences of various AAV serotype capsid proteins, that an insertion site "corresponding to amino acids 587-588 of AAV2" will be present in the capsid protein of any given AAV serotype.
[0049]
[0068] In some cases, exogenous polypeptides may have 0 to 4 spacer amino acids (Y1 to Y4) at any one amino-terminus and / or carboxyl-terminus of the exemplary polypeptides in Table 2 or Formula 1. Preferred spacer amino acids include, but are not limited to, leucine, alanine, glycine, and / or serine.
[0050]
[0069] Modifications to the AAV capsid may involve modifications of at least one amino acid residue in the polypeptide sequence. In some cases, modifications may be made at any AAV capsid position as described herein and may involve any number of modifications. In some cases, modifications may involve mutations. Mutations may include point mutations, missense mutations, nonsense mutations, deletions, duplications, frameshifts, and / or repeat extensions.
[0051]
[0070] In one embodiment, the amino acid may be a nonpolar aliphatic residue, such as glycine, alanine, valine, leucine, isoleucine, or proline. In one embodiment, the amino acid residue may be aromatic, such as phenylalanine, tyrosine, or tryptophan. In one embodiment, the amino acid residue may be polar and uncharged, such as serine, threonine, cysteine, methionine, asparagine, or glutamine. In one embodiment, the amino acid may be positively charged, such as lysine, arginine, or histidine. In one embodiment, the amino acid may be negatively charged, such as aspartate or glutamate.
[0052]
[0071] In some cases, the mutation is a point mutation. A point mutation involves a change from a charged amino acid residue to a polar or nonpolar amino acid residue. In some cases, the charged amino acid is positively charged. In some cases, the charged amino acid is negatively charged.
[0053]
[0072] Point mutations can be conservative mutations. Non-limiting examples of conservative mutations include mutations from nonpolar aliphatic amino acids to nonpolar aliphatic amino acids, polar amino acids to polar amino acids, positively charged amino acids to positively charged amino acids, negatively charged amino acids to negatively charged amino acids, and aromatic amino acids to aromatic amino acids. For example, 20 naturally occurring amino acids may share similar properties. Aliphatic amino acids may be glycine, alanine, valine, leucine, or isoleucine. Hydroxyl or sulfur / selenium-containing amino acids may be serine, cysteine, selenocysteine, threonine, or methionine. Cyclic amino acids may be proline. Aromatic amino acids may be phenylalanine, tyrosine, or tryptophan. Basic amino acids may be histidine, lysine, and arginine. Acidic amino acids may be aspartate, glutamate, asparagine, or glutamine. Conservative mutations can be serine to glycine, serine to alanine, serine to serine, serine to threonine, and serine to proline. Conservative mutations can be arginine to asparagine, arginine to lysine, arginine to glutamine, arginine to arginine, and arginine to histidine. Conservative mutations can be leucine to phenylalanine, leucine to isoleucine, leucine to valine, leucine to leucine, and leucine to methionine. Conservative mutations can be proline to glycine, proline to alanine, proline to serine, proline to threonine, and proline to proline. Conservative mutations can be threonine to glycine, threonine to alanine, threonine to serine, threonine to threonine, and threonine to proline. Conservative mutations can be alanine to glycine, alanine to threonine, alanine to proline, alanine to alanine, and alanine to serine. Conservative mutations can be from valine to methionine, valine to phenylalanine, valine to isoleucine, valine to leucine, or valine to valine. Conservative mutations can also be from glycine to alanine, glycine to threonine, glycine to proline, glycine to serine, or glycine to glycine.Conservative mutations can be from isoleucine to phenylalanine, isoleucine to isoleucine, isoleucine to valine, isoleucine to leucine, and isoleucine to methionine. Conservative mutations can be from phenylalanine to tryptophan, phenylalanine to phenylalanine, and phenylalanine to tyrosine. Conservative mutations can be from tyrosine to tryptophan, tyrosine to phenylalanine, and tyrosine to tyrosine. Conservative mutations can be from cysteine to serine, cysteine to threonine, and cysteine to cysteine. Conservative mutations can be from histidine to asparagine, histidine to lysine, histidine to glutamine, histidine to arginine, and histidine to histidine. Conservative mutations can be from glutamine to glutamic acid, glutamine to asparagine, glutamine to aspartic acid, and glutamine to glutamine. Conservative mutations can occur from asparagine to glutamic acid, asparagine to asparagine, asparagine to aspartic acid, and asparagine to glutamine. Conservative mutations can occur from lysine to asparagine, lysine to lysine, lysine to glutamine, lysine to arginine, and lysine to histidine. Conservative mutations can occur from aspartic acid to glutamic acid, aspartic acid to asparagine, aspartic acid to aspartic acid, and aspartic acid to glutamine. Conservative mutations can occur from glutamine to glutamine, glutamine to asparagine, glutamine to aspartic acid, and glutamine to glutamine. Conservative mutations can occur from methionine to phenylalanine, methionine to isoleucine, methionine to valine, methionine to leucine, and methionine to methionine. Conservative mutations can occur from tryptophan to tryptophan, tryptophan to phenylalanine, and tryptophan to tyrosine.
[0054]
[0073] Further non-limiting examples of amino acid mutations include A to R, A to N, A to D, A to C, A to Q, A to E, A to G, A to H, A to I, A to L, A to K, A to M, A to F, A to P, A to S, A to T, A to W, A to Y, A to V, R to N, R to D, R to C, R to Q, R to E, R to G, R to H, R to I, R to L, R to K, R to M, R to F, R to P, R to S, R to T, R to W, R to Y, R to V, N to D, N to C, N to Q, N to E, N to G, N to H, N to I, N to L, N to K N to M, N to F, N to P, N to S, N to T, N to W, N to Y, N to V, D to C, D to Q, D to E, D to G, D to H, D to I, D to L, D to K, D to M, D to F, D to P, D to S, D to T, D to W, D to Y, D to V, C to Q, C to E, C to G, C to H, C to I, C to L, C to K, C to M, C to F, C to P, C to S, C to T, C to W, C to Y, C to V, Q to E, Q to G, Q to H, Q to I, Q to L, Q to K, Q to M, Q to F, Q to P, Q to S, Q From T, Q to W, Q to Y, Q to V, E to G, E to H, E to I, E to L, E to K, E to M, E to F, E to P, E to S, E to T, E to W, E to Y, E to V, G to H, G to I, G to L, G to K, G to M, G to F, G to P, G to S, G to T, G to W, G to Y, G to V, H to I, H to L, H to K, H to M, H to F, H to P, H to S, H to T, H to W, H to Y, H to V, I to L, I to K, I to M, I to F, I to P, I to S, I to T, I to W, I to Y, I to V, L to K, L to M, L to F, L to P, L to S, L to T, L to W, L to Y, L to V, K to M, K to F, K to P, K to S, K to T, K to W, K to Y, K to V, M to F, M to P, M to S, M to T, M to W, M to Y, M to V, F to P, F to S, F to T, F to W, F to Y, F to V, P to S, P to T, P to W, P to Y, P to V, S to T, S to W, S to Y, S to V, T to W, T to Y, T to V, W to Y, W to V, Y to V, and the reverse of any of the mutations described above.
[0055]
[0074] Any of the aforementioned modifications, insertions, deletions, and / or mutations can be made at any residue in the AAV sequence. The sequence may be a capsid sequence. In other cases, the sequence may be a Rep sequence and / or an X sequence rather than a capsid sequence. The sequence may be VP1, VP2, and / or VP3 as previously described. In some cases, the modification of the sequence is a modification of a loop in the capsid sequence, e.g., loop 3 and / or loop 4. In some cases, the modification is a modification of residues in the sequence shown in Table 1.
[0056]
[0075]
[0057] [Table 1-1]
[0058] [Table 1-2]
[0059] [Table 1-3]
[0060]
[0076] In some cases, modifications, such as insertions, deletions, and / or mutations, are modifications of residues in the capsid polypeptide sequence shown in Table 1. In some cases, modifications are at positions 1-100, 100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, or combinations thereof. In some cases, modifications are made at residues at positions 200-300, 300-400, 400-500, 500-600, or combinations thereof. In some cases, modifications are made at residues at positions 300-500 or combinations thereof. In one embodiment, the insertion site is in the GH loop or loop IV of the AAV capsid protein, for example, in a solvent-accessible portion of the GH loop or loop IV of the AAV capsid protein. For more information on GH loops, see, for example, van Vliet et al. (2006) Mol. Ther. 14:809; Padron et al. (2005) J. Virol. 79:5047; and Shen et al. (2007) Mol. Ther. 15:1955. For example, insertion sites are within amino acids 570-611 of AAV2, 571-612 of AAV1, 560-601 of AAV5, 571-612 of AAV6, 572-613 of AAV7, 573-614 of AAV8, 571-612 of AAV9, or 573-614 of AAV10.
[0061]
[0077] For example, the insertion site could be between amino acids 587 and 588 of AAV2, between amino acids 590 and 591 of AAV1, between amino acids 575 and 576 of AAV5, between amino acids 590 and 591 of AAV6, between amino acids 589 and 590 of AAV7, between amino acids 590 and 591 of AAV8, between amino acids 588 and 589 of AAV9, or between amino acids 589 and 590 of AAV10. In some cases, the modification is made at positions 452, 453, 466, 467, 468, 471, 585, 586, 587, and / or 588 of AAV2. In some cases, the modification is made at position 452 or 453 of AAV2. In some cases, the modification is made at position 587 or 588 of AAV2. In some cases, the modification is an insertion at positions 452, 453, 466, 467, 468, 471, 585, 586, 587, and / or 588 of sequence number 1. In some cases, the modification is a mutation, which is R585A or R588A of sequence number 1.
[0062]
[0078] In some embodiments, the modified AAV capsid of the subject does not contain any other amino acid modifications, such as mutations, substitutions, insertions, or deletions, other than the insertion of about 5 to about 11 amino acids in the loops (loops 3 and / or 4) compared to the corresponding unmodified AAV capsid protein. In other embodiments, the variant AAV capsid of the subject includes insertions, deletions, or substitutions of 1 to about 25 amino acids compared to the unmodified AAV capsid protein, in addition to the insertion of about 5 to about 11 amino acids in loops 3 and / or loop 4 compared to the unmodified AAV capsid protein. In one embodiment, the AAV virion capsid of the subject does not contain any other amino acid substitutions, insertions, or deletions, other than the insertion of about 7 to about 10 amino acids in the GH loop or loop IV compared to the corresponding parent AAV capsid protein. In other embodiments, the subject AAV virion capsid includes, in addition to, approximately 7 to approximately 10 amino acid insertions in the GH loop or loop IV compared to the corresponding parent AAV capsid protein, insertions, deletions, or substitutions of 1 to approximately 25 amino acids compared to the parent AAV capsid protein. For example, in some embodiments, the subject AAV virion capsid includes, in addition to, approximately 7 to approximately 10 amino acid insertions in the GH loop or loop IV compared to the corresponding parent AAV capsid protein, insertions, deletions, or substitutions of 1 to approximately 5, approximately 5 to approximately 10, approximately 10 to approximately 15, approximately 15 to approximately 20, or approximately 20 to approximately 25 amino acids compared to the parent AAV capsid protein.
[0063]
[0079] In some cases, chimeric AAV capsids are provided herein. A chimeric capsid comprises polypeptide sequences derived from at least two AAV serotypes. A chimeric capsid may comprise a mix of sequences selected from serotypes AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, and / or AAV13. In some cases, the chimeric serotypes differ among VP1, VP2, and / or VP3. In some cases, the chimeric capsid comprises sequences derived from at least two serotypes selected from AAV4 and AAV6, AAV5 and AAV6, AAV11 and AAV6, AAV12 and AAV6, and any combination thereof. In some cases, the first AAV serotype may be AAV4 and the second serotype may be AAV6. In some cases, the first and second AAV serotypes of the chimeric AAV vector may be AAV11 and AAV6. In some cases, the first and second AAV serotypes of the chimeric AAV vector may be AAV12 and AAV6. In some cases, the chimeric capsid contains a sequence selected from AAV2 and AAV5 or AAV2 and AAV6. In some cases, the chimeric capsid contains a sequence selected from AAV2 and AAV5, AAV2 and AAV6, AAV2 and AAV8, AAV2 and AAV9, AAV2 and AAV1, and AAV2 and AAV12.
[0064]
[0080] Modifications to AAV provided herein may confer enhanced activity to the modified AAV compared to another unmodified or wild-type AAV. Modifications provided herein may improve cell transduction, tropism, and / or reduce capsid-related immunogenicity.
[0065]
[0081] In some cases, the modifications provided herein enhance the transduction of cells. Transduction of cells may mean the ability of AAV to infect cells (in vivo or in vitro) and / or the ability to deliver transgenes to cells.
[0066]
[0082] In some cases, the modifications provided herein enhance tropism. Enhanced tropism means acquiring the ability to transduce cells by extra receptors compared to another unmodified AAV. In some embodiments, enhanced tropism can improve the infectivity of ophthalmic cells, thereby improving gene therapy using the modified AAV. In some cases, the modifications provided herein may improve tropism to ophthalmic cells selected from bipolar cells, retinal ganglion cells, horizontal cells, amacrine cells, epithelial cells, retinal pigment cells, photoreceptors, or any combination thereof. In some cases, the modifications improve tropism to retinal cells.
[0067]
[0083] Furthermore, AAV vectors are also provided herein. AAV vectors include a reverse-terminal repeat (ITR), Rep, Cap, AAP, and X sequences. Typically, the AAV viral genome is flanked by an ITR that functions as a packaging signal and replication origin. The rep gene encodes a family of multifunctional proteins (Rep proteins) responsible for regulating viral transcription, replication, packaging, and integration in AAVS1. For AAV2, four Rep proteins are described. The expression of Rep78 and Rep68 is regulated by the AAV2-specific p5 promoter, while p19 regulates the expression of smaller Rep proteins (Rep52 and Rep40). Rep68 and Rep40 are splice variants of Rep78 and Rep52, respectively. The numbers indicate molecular weight. The expression of AAP and viral capsid proteins VP1 (90 kDa), VP2 (72 kDa), and VP3 (60 kDa), all encoded in the cap gene, is regulated by the p40 promoter. The X gene is located at the 3' end of the genome within the region shared by the cap gene and possesses its own promoter (p81). While the X protein is thought to enhance viral replication, AAP is essential for capsid assembly. These three distinct VPs contribute to the icosahedral AAV2 capsid in a ratio of 1 (VP1):1 (VP2):10 (VP3).
[0068]
[0084] The modified capsid proteins disclosed herein can be isolated, for example, purified. In some embodiments, the modified capsids disclosed herein are contained in AAV vectors or AAV virions (e.g., recombinant AAV virions, rAAV). In other embodiments, such modified AAV vectors and / or AAV variant virions are used in in vivo or ex vivo methods to treat eye diseases in primate retinas, for example, human retinas.
[0069]
[0085] Vectors containing modified AAV capsids are also provided herein. Any of the modifications described above may be incorporated into the vectors provided herein. In some cases, the AAV vector contains a modified capsid that includes an exogenous sequence in at least two loops of the VP domain, compared to an otherwise equivalent AAV capsid sequence lacking the exogenous sequence. In some embodiments, the vectors provided herein may further include a transgene sequence.
[0070]
[0086] Methods for modifying AAV capsids from WT capsid proteins are also disclosed herein. An exemplary method for producing a modified capsid is described in Example 2 herein. In some cases, a method for producing a modified capsid containing a mutation involves subjecting a nucleic acid containing the nucleotide sequence encoding the WT capsid protein to a type of mutagenesis selected from the group consisting of polymerase chain reaction mutagenesis, oligonucleotide-specific mutagenesis, saturation mutagenesis, loop exchange mutagenesis, fragment shuffling mutagenesis, and combinations thereof. In some embodiments, the mutation in the AAV cap of interest is generated using any known method. Preferred methods for mutagenesis of the AAV cap gene include, but are not limited to, polymerase chain reaction (PCR)-based methods and oligonucleotide-specific mutagenesis. Methods for generating mutations have been well described in the Art. For example, see Zhao et al. (1998) Nat. Biotechnol. 16:234~235; U.S. Patent Nos. 6,579,678; 6,573,098; and 6,582,914.
[0071]
[0087] In one embodiment, the mutant capsids disclosed herein can be generated by using an AAV library. Such AAV libraries are generated by mutating the cap gene encoding the structural protein of the AAV capsid using various directional evolution methods, for example: Bartel et al. Am. Soc. Gene Cell Ther. 15th Annu. Meet. 20, S140 (2012); Bowles, D. et al. J. Virol. 77, 423~432 (2003); Gray et al. Mol. Ther. 18, 570~578 (2010); Grimm, D. et al. J. Virol. 82, 5887~5911; Koerber, JT et al. Mol. Ther. 16, 1703~1709 (2008); Li W. et al. Mol. Ther. 16, 1252~1260 (2008); Koerber, JT et al. Methods Mol. Biol. 434, 161~170 See (2008); Koerber, JT et al. Hum. Gene Ther. 18, 367~378 (2007); and Koerber, JT et al. Mol. Ther. 17, 2088~2095 (2009).Such techniques, though not limited to these, include: i) error-prone PCR to introduce random point mutations into an AAV cap open reading frame (ORF) at a predetermined moduloable rate; ii) in vitro or in vivo viral recombination or "DNA shuffling" to produce random chimeras of the AAV cap gene to obtain a gene library of multiple AAV serotypes; iii) random peptide insertion at the capsid determination site by ligation of degenerate oligonucleotides in the cap ORF; iv) predetermined insertion of peptide coding sequences into random positions in the AAV cap ORF using transposon mutagenesis; v) replacing the surface loop of the AAV capsid with a library of bioinformationally designed peptide sequences based on the level of conservation of each amino acid position among native AAV serotypes and variants to generate a "loop-swapping" library; vi) random amino acid substitution at degenerate positions among AAV serotypes to generate a library of ancestral variants (Santiago-Ortiz et al., 2015); and combinations of such techniques.
[0072]
[0088] In some embodiments, the modified capsid can be generated using a staggered extension process. The staggered extension process involves amplification of the cap gene using a PCR-based method. The template cap gene is primed using specific PCR primers, followed by repeated cycles of denaturation and very short annealing / polymerase-catalyzed extension. In each cycle, the growth fragment anneals to a different template based on sequence complementarity and extends further. The cycles of denaturation, annealing, and extension are repeated until a full-length sequence is formed. The resulting full-length sequence contains at least one mutation in the cap gene compared to the wild-type AAV cap gene. The PCR product containing the AAV cap sequence containing one or more mutations is inserted into a plasmid containing the wild-type AAV genome. The result is a library of AAV cap variants. Thus, this disclosure is approximately 10 to approximately 10 10 This provides a mutant AAV cap gene library that includes members and also contains mutations in the AAV cap gene. Members of a given library have approximately 1 to 50 mutations in the AAV cap gene. The subject library has 10 to approximately 10 9 It contains different members, each having a different mutation(s) in the AAV cap gene. After the cap mutant library is generated, viral particles are produced and can then be selected based on the characteristics of the altered capsid. The library plasmid DNA is transfected into suitable target host cells (e.g., 293 cells and / or ARPE-19 cells) and subsequently introduced into the cells with the helper virus. Viral particles produced by the transfected host cells ("AAV library particles") are collected.
[0073]
[0089] In one embodiment, after the AAV library is generated, the virions are then packaged so that each AAV particle consists of a modified capsid surrounding the cap gene encoding its capsid, and are purified. In some cases, variants of the library, including the modification, are then subjected to in vitro and / or in vivo selective pressure techniques known to those skilled in the art of AAV and readily available. For example, see Maheshri, N. et al. Nature Biotech. 24, 198~204 (2006); Dalkara, D. et al. Sci. Transl. Med. 5, l89ra76 (2013); Lisowski, L. et al. Nature. 506, 382~286 (2013); Yang, L. et al. PNAS. 106, 3946~3951 (2009); Gao, G. et al. Mol. Ther. 13, 77~87 (2006); and Bell, P. et al. Hum. Gene. Ther. 22, 985~997 (2011). For example, but not limited to, modified AAVs can be selected using: i) affinity columns yielding variants with altered binding properties due to the elution of different fragments; ii) primary cells isolated from tissue samples or immortalized cell lines mimicking the behavior of human cells yielding AAV variants with increased efficacy and / or tissue specificity; iii) animal models mimicking clinical gene therapy environments yielding AAV variants that successfully infect target tissues; iv) human xenograft models yielding AAV variants, including the modification of the subject, that infect grafted human cells; and / or selected combinations of these techniques. After the virions are selected, they can be recovered by known techniques, such as, but not limited to, adenovirus-mediated replication, PCR amplification, next-generation sequencing, and cloning. Subsequently, by repeating rounds of selection techniques, viral clones are enriched and AAV DNA is isolated to recover the desired selected variant cap gene.Such selected variants can be subjected to further modification or mutation, and thus can serve as a new starting point for further selection processes to repeatedly increase AAV virus adaptability. However, in certain cases, good capsids were generated without additional mutations.
[0074]
[0090] The modified AAVs of the subject disclosed herein can be generated by the use of in vivo directional evolution, accompanied by the use of primate retinal screening after intravitreous administration. In some embodiments, the modified capsid proteins disclosed herein, when present in AAV virions, give increased transduction of retinal cells compared to transduction of retinal cells by AAV virions containing the corresponding parental AAV capsid protein or wild-type AAV. For example, in some embodiments, the variant capsid proteins disclosed herein, when present in AAV virions, give more efficient transduction of primate retinal cells than AAV virions containing the corresponding parental AAV capsid protein or wild-type AAV capsid protein, for example, retinal cells take up more AAV virions containing the target variant AAV capsid protein than AAV virions containing the parental AAV capsid protein or wild-type AAV.
[0075]
[0091] Methods for treating diseases or conditions in subjects requiring treatment of a disease or condition are also provided herein. The subject method may include administering a therapeutically effective amount of a pharmaceutical composition comprising an adeno-associated virus (AAV) vector comprising an adeno-associated virus (AAV) vector comprising a modified capsid containing an exogenous polypeptide sequence in the VP domain of an AAV capsid, compared to otherwise equivalent unmodified AAV capsids, wherein the exogenous polypeptide sequence comprises the sequence of Formula 1: X0-X1-X2-X1-X3-X1-X1-X4 (SEQ ID NO: 108), where X0 is valine (V), isoleucine (I), leucine (L), phenylalanine (F), X1 is tryptophan (W), tyrosine (Y), or methionine (M), where X1 is alanine (A), asparagine (N), glutamine (Q), serine (S), threonine (T), glutamic acid (E), aspartic acid (D), lysine (K), arginine (R), or histidine (H), where X2 is V, I, L, or M, where X3 is E, S, or Q, where X4 is K, R, E, or A, and optionally further includes X5 where formula 1 is proline (P) or R.
[0076]
[0092] In some cases, the subject AAV vector contains sequences that have at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NOs. 47. In one embodiment, the AAV vector contains a modified capsid of SEQ ID NO. 34.
[0077]
[0093] Engineered AAV virions containing modified AAV capsids are also provided herein. Engineered AAV virions can be generated using host cells or “producer” cells for rAAV vector replication and packaging. Such producer cells (typically mammalian host cells) generally contain or are modified to contain several different types of components for rAAV production. The first component is a recombinant adeno-associated virus (rAAV) vector genome (or “engineered AAV”) that can be replicated by host packaging cells and packaged within vector particles. The rAAV pro-vector may contain a subject transgene by which it is desired to genetically modify another cell in connection with gene therapy (because packaging such a transgene into rAAV vector particles can be effectively used to deliver the transgene to various mammalian cells). The transgene generally flanks two AAV reverse terminal repeat sequences (ITRs) containing sequences that are recognized during AAV vector removal, replication, and packaging, as well as during the integration of the vector into the host cell genome.
[0078]
[0094] Another component may be a helper virus that can provide helper function for AAV replication. Adenoviruses are commonly used, but other helper viruses known in the art can also be used. Alternatively, the required helper virus function can be genetically isolated from the helper virus, and the coding gene can be used to provide the helper virus function in trans. The AAV vector elements and the helper virus (or helper virus function) can be introduced into host cells simultaneously or sequentially in no particular order.
[0079]
[0095] The additional components for AAV production provided to producer cells are "AAV packaging genes," such as AAV rep and cap genes, which provide replication and capsid-forming proteins, respectively. Several different variations of AAV packaging genes can be provided, including rep-cap cassettes and separate rep and / or cap cassettes, where the rep and / or cap genes can be left under the control of a native promoter or operably linked to a heterologous promoter. Such AAV packaging genes are known in the art and can be introduced into host packaging cells either transiently or stably, as will be described in more detail below.
[0080]
[0096] This disclosure further provides, in this specification, host cells, for example, isolated (genetically modified) host cells containing the nucleic acid of the subject, etc. Host cells according to the inventions disclosed herein may be isolated cells, for example, cells derived from in vitro cell cultures, etc. Such host cells are useful for the production of the modified AAV virions of the subject described herein. In one embodiment, such host cells are stably genetically modified with nucleic acid. In other embodiments, host cells are transiently genetically modified with nucleic acid. Such nucleic acid is stably or transiently introduced into host cells using established techniques, for example, electroporation, calcium phosphate precipitation, liposome-mediated transfection, etc. For stable transformation, the nucleic acid will generally further include a selectable marker, for example, any of several well known selectable markers, such as neomycin resistance, etc. Such host cells are produced by introducing nucleic acid into any of the following cells, for example, mammalian cells, for example, mouse cells, and primate cells (for example, human cells). Examples of mammalian cells include, but are not limited to, primary cells and cell lines. In this case, examples of cell lines include, but are not limited to, 293 cells, COS cells, HeLa cells, Vero cells, 3T3 mouse fibroblasts, C3H10T1 / 2 fibroblasts, and CHO cells.Examples of host cells, though not limited to these, include HeLa cells (e.g., American Type Culture Collection (ATCC) number CCL-2), CHO cells (e.g., ATCC numbers CRL9618, CCL61, CRL9096), 293 cells (e.g., ATCC number CRL-1573), Vero cells, NIH3T3 cells (e.g., ATCC number CRL-1658), Huh-7 cells, BHK cells (e.g., ATCC number CCL10), PC12 cells (ATCC number CRL1721), COS cells, COS7 cells (ATCC number CRL1651), RAT1 cells, mouse L cells (ATCC number CCLI.3), human embryonic kidney (HEK) cells (ATCC number CRL1573), and HLHepG2 cells. Host cells can also be prepared by using baculovirus to infect insect cells that produce AAV, such as Sf9 cells (see, for example, U.S. Patent No. 7,271,002; U.S. Patent Application No. 12 / 297,958). In some embodiments, the genetically modified host cell includes a nucleic acid containing a nucleotide sequence encoding one or more AAV rep proteins, in addition to a nucleic acid containing a nucleotide sequence encoding the variant AAV capsid protein described above. In other embodiments, the host cell further includes the subject vector. Modified virions of the subject can be produced using such host cells. Methods for producing virions are described, for example, in U.S. Patent Application Publication No. 2005 / 0053922 and U.S. Patent Application Publication No. 2009 / 0202490.
[0081]
[0097] In some cases, engineered AAV virions of the subject, including transgenes, can be produced using methodologies known to those skilled in the art. These methods generally involve: (1) introducing an engineered AAV vector of the subject into a host cell; (2) introducing an AAV helper construct into a host cell, wherein the helper construct includes an AAV coding region that can be expressed in the host cell to compensate for the AAV helper function lost from the AAV vector; (3) introducing one or more helper viruses and / or accessory functional vectors into a host cell, wherein the helper viruses and / or accessory functional vectors provide accessory functions that can support efficient recombinant AAV ("rAAV") virion production in the host cell; and (4) culturing the host cell to produce engineered AAV virions. AAV expression vectors, AAV helper constructs, and helper viruses or accessory functional vectors(s) can be introduced into host cells either simultaneously or sequentially using standard transfection techniques. The AAV expression vector is constructed using known techniques to provide at least a component operably linked in the direction of transcription, a regulatory element containing a transcription start region, the DNA of interest, and a transcription end region. The regulatory element can be selected to be functional in mammalian muscle cells. The resulting construct, including the operably linked component, can be conjugated to a functional AAV ITR sequence (5' and 3').
[0082]
[0098] In some cases, known nucleotide sequences of AAV ITRs can be used for AAV-2 sequences; see, for example, Kotin, RM (1994) Human Gene Therapy 5:793~801; Berns, KI "Parvoviridae and their Replication" in Fundamental Virology, 2nd Edition, (BN Fields and DM Knipe, eds.). In some embodiments, the AAV ITRs used in the compositions and methods provided herein do not need to have wild-type nucleotide sequences and may be modified, for example, by nucleotide insertions, deletions, or substitutions. Furthermore, AAV ITRs can be obtained from any of the AAV serotypes provided herein, for example, but not limited to, AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-7, etc. Furthermore, the 5' and 3' ITRs adjacent to the selected nucleotide sequence in the AAV expression vector do not necessarily need to be identical to or derived from the same AAV serotype or isolate, as long as they function as intended—that is, as long as they enable the removal and rescue of the target sequence originating from the host cell genome or vector, and enable the integration of the DNA molecule into the recipient cell genome if the AAV Rep gene product is present in the cell. The ITRs enable the replication of the vector sequence in the presence of a suitable mixture of Rep proteins. The ITRs also enable the incorporation of the vector sequence into the capsid to generate AAV particles.
[0083]
[0099] This disclosure provides adeno-associated virus (AAV) virions with a modified capsid protein, in which case the AAV virions exhibit higher infectivity to ophthalmic cells compared to unmodified AAVs such as wild-type AAV when administered by intravitreal injection. This disclosure further provides methods for delivering transgenes to cells such as retinal cells and for treating eye diseases. Retinal cells may be photoreceptor cells (e.g., rods:cones), retinal ganglion cells (RGCs), Müller cells (Müller glial cells), bipolar cells, amacrine cells, horizontal cells, or retinal pigment epithelium (RPE) cells.
[0084]
[0100] A method for treating a disease or condition in a subject requiring treatment of the disease or condition is also provided herein, comprising the step of administering a therapeutically effective dose of a pharmaceutical composition comprising an adeno-associated virus (AAV) vector comprising a modified capsid. In some cases, the modified capsid comprises an exogenous polypeptide sequence in at least two loops of the VP domain compared to an otherwise equivalent AAV capsid sequence lacking the exogenous polypeptide sequence. In some embodiments, the exogenous polypeptide sequence comprises the sequences shown in Table 2. In some cases, the subject AAV vector further comprises a sequence comprising a transgene. A method for treating a disease or condition in a subject requiring treatment of the disease or condition is also provided, comprising the step of administering a therapeutically effective dose of a pharmaceutical composition comprising an adeno-associated virus (AAV) vector. The subject AAV vector may comprise (a) a modified capsid comprising an exogenous sequence in at least two loops of the VP domain compared to an otherwise equivalent AAV capsid sequence lacking the exogenous sequence; and / or (b) a transgene. In some cases, when the vector comes into contact with multiple cells, it results in at least a 3-fold, 4-fold, 5-fold, 10-fold, 15-fold, 30-fold, 60-fold, or 100-fold increase in the expression of the transgene after transfection in multiple cells compared to contact with multiple cells with other equivalent AAV vectors lacking (a). In some cases, the increase in expression includes at least a 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 200-fold, or 500-fold increase compared to contact with multiple cells with other equivalent AAV vectors lacking (a).
[0085]
[0101] Compositions comprising AAV virions of multiple subjects are also provided herein. Manipulated cells produced by transfecting cells with an AAV vector of a subject or an AAV virion of a subject are also provided. In some embodiments, viral particles can be isolated from the manipulated cells of a subject. Multiple adeno-associated virus (AAV) particles isolated from the manipulated cells can also be provided. Furthermore, compositions comprising adeno-associated virus particles in unit dosage forms are provided. In some cases, the compositions of a subject can be stored at low temperatures.
[0086]
[0102] Transgenes are also provided herein. Suitable transgenes include, but are not limited to, those that encode proteins used to treat diseases. In some embodiments, the disease is an eye disease. In another embodiment, a suitable disease may be a retinal disease. In some embodiments, the transgene can encode a therapeutic agent, such as an ophthalmic therapeutic agent. An ophthalmic therapeutic agent may be effective in reducing symptoms of a disease, such as an eye disease. In some embodiments, the therapeutic agent may reduce symptoms of a retinal disease, treat a retinal disease, or It may be effective in eliminating retinal diseases. Suitable ophthalmic therapeutic agents may mean antibodies or their bioactive fragments and / or biologics. Targets of antibodies and biologics may include PDGF-BB, C5 complement, C3 complement, TNF-alpha, VEGF-A, VEGFR01, DDIT4, KSP, PEDF, VEGF, VEGFL, thrombospondin 1, CD47, alpha-5 beta-1 integrin, endostatin, angiostatin, pathological blood vessels, or any combination thereof.
[0087]
[0103] In some cases, the ophthalmic therapeutic agent is an antibody or a bioactive fragment thereof. The antibody may be a monoclonal antibody. In some cases, the antibody may be a fully human antibody or a humanized antibody. Preferred antibodies may be anti-VEGF, anti-VEGFL, anti-thrombospondin 1, anti-CD47, anti-TNF-alpha, anti-CD20, anti-CD52, and anti-CD11a, anti-complement factor 5, and / or anti-complement factor 3. In some cases, the antibody or bioactive fragment includes rituximab, infliximab, ranibizumab, bevacizumab, JSM6427, and / or convacept.
[0088]
[0104] In another embodiment, the antibody is a single-chain version of ranibizumab (Sc-ranibizumab). Ranibizumab is a monoclonal IgG1 antibody fragment (Fab) that binds to and blocks all isoforms of VEGF-A. Ranibizumab is expressed in bacteria as two separate chains (light chain and heavy chain) linked by a disulfide bond between the constant light chain (CL) and constant heavy chain 1 (CH1) domains. The approved dose of intravitreous ranibizumab is either 0.3 mg or 0.5 mg in 0.05 mL, depending on the indication. Ranibizumab is approved for the treatment of exudative age-related macular degeneration, macular edema after retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.
[0089]
[0105] In some cases, the ophthalmic therapeutic agent is a biologic. In some embodiments, the biologic is selected from macromolecules, e.g., proteins, peptides, aptamers, and / or non-coding RNAs, e.g., antisense RNA, ribozymes, RNAi, and siRNA. In some embodiments, the compositions provided herein, e.g., AAV virion comprising a modified capsid, include a transgene encoding the therapeutic agent. In some embodiments, the therapeutic agent is interfering RNA. In some embodiments, the therapeutic agent is an aptamer. In some embodiments, the therapeutic agent is a polypeptide. In some embodiments, the therapeutic agent is a site-selective nuclease that provides site-selective knockdown of gene function.
[0090]
[0106] In some cases, the biologic is a DNA aptamer, RNA aptamer, dual siRNA, gene, polypeptide, or protein scaffold. In some cases, the biologic is selected from lipoprotein lipase, retinoid isomerohydrolase RPE65, or complement factor H. In some cases, the biologic includes siRNA targeting VEGF-A, e.g., bevacilanib. In some cases, the biologic is an RNA aptamer, e.g., pegaptanib. In some cases, the biologic is a polypeptide, e.g., a fusion protein, e.g., aflibercept. In some cases, the biologic is a DNA aptamer, e.g., Fovista. In some cases, the biologic is a protein scaffold, e.g., DARPins.
[0091]
[0107] In one embodiment, the biologic is aflibercept. Aflibercept may be a recombinant fusion protein containing the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc protein of human IgG1. Aflibercept functions as a soluble decoy receptor that binds to VEGF-A and PDGF with higher affinity than the innate receptors. The approved indication for intravitreal aflibercept injection is 2.0 mg, and its dosage varies according to the indication. Aflibercept is indicated for the treatment of neovascular (exudative) age-related macular degeneration, macular edema after retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.
[0092]
[0108] In some embodiments, the biological therapeutic agent is an aptamer, and an exemplary aptamer of interest is an aptamer for vascular endothelial growth factor (VEGF). See, for example, Ng et al. (2006) Nat. Rev. Drug Discovery 5:123; and Lee et al. (2005) Proc. Natl. Acad. Sci. USA 102:18902. For example, a VEGF aptamer may contain the nucleotide sequence 5'-cgcaaucagugaaugcuuauacauccg-3' (SEQ ID NO: 109). PDGF-specific aptamers, such as E10030, are also suitable for use; see, for example, Ni and Hui (2009) Ophthalmologica 223:401; and Akiyama et al. (2006) J. Cell Physiol. 207:407).
[0093]
[0109] In some embodiments, the biological therapeutic agent is an interfering RNA (RNAi), and preferred RNAi include RNAi that can reduce the levels of apoptotic or angiogenic factors in cells. For example, the RNAi may be shRNA or siRNA that reduces the levels of gene products that induce or promote apoptosis in cells. Genes whose gene products induce or promote apoptosis are referred to herein as “pro-apoptotic genes,” and their products (mRNA; proteins) are referred to as “pro-apoptotic gene products.” Examples of pro-apoptotic gene products include the Bax, Bid, Bak, and Bad gene products. See, for example, U.S. Patent No. 7,846,730. Interfering RNAs may also be those related to vascular products, such as VEGF (e.g., Cand5; see, for example, U.S. Patent Application Publication No. 2011 / 0143400; U.S. Patent Application Publication No. 2008 / 0188437; and Reich et al. (2003) Mol. Vis. 9:210), VEGFR1 (e.g., Sirna-027; see, for example, Kaiser et al. (2010) Am. J. Ophthalmol. 150:33; and Shen et al. (2006) Gene Ther. 13:225), or VEGFR2 (Kou et al. (2005) Biochem. 44:15064). See also U.S. Patent Nos. 6,649,596, 6,399,586, 5,661,135, 5,639,872, and 5,639,736; and U.S. Patent Nos. 7,947,659 and 7,919,473.
[0094]
[0110] In some cases, biologics contain polypeptides. Polypeptides can enhance the function of retinal cells, such as rod or cone photoreceptor cells, retinal ganglion cells, Müller cells, bipolar cells, amacrine cells, horizontal cells, or retinal pigment epithelial cells. Examples of polypeptides include neuroprotective polypeptides (e.g., GDNF, CNTF, NT4, NGF, and NTN); anti-angiogenic polypeptides (e.g., soluble vascular endothelial growth factor (VEGF) receptors; VEGF-binding antibodies; VEGF-binding antibody fragments (e.g., single-chain anti-VEGF antibodies); endostatins; tamstatins; angiostatins; soluble Flt polypeptides (Lai et al. (2005) Mol. Ther. 12:659); Fc fusion proteins containing soluble Flt polypeptides (see, for example, Pechan et al. (2009) Gene Ther. 16:10); pigment epithelial-derived factor (PEDF); soluble Tie-2 receptors, etc.); metalloproteinase-3 tissue inhibitors (TIMP-3); photoreactive opsins, e.g., rhodopsin; and anti-apoptotic polypeptides (e.g., Bcl-2, Bcl-X1). Suitable polypeptides include, but are not limited to, glial neurotrophic factor (GDNF); fibroblast growth factor 2; neuruturin (NTN); ciliary neurotrophic factor (CNTF); nerve growth factor (NGF); neurotrophin-4 (NT4); brain-derived neurotrophic factor (BDNF); epidermal growth factor; rhodopsin; X-linked inhibitors of apoptosis; and sonic hedgehog.
[0095]
[0111] In some cases, polypeptides include retinosoxin, retinitis pigmentosa GTPase regulator (RGPR)-interacting protein-1 (see, e.g., GenBank accession numbers Q96KN7, Q9EPQ2, and Q9GLM3), peripherin-2 (Prph2) (see, e.g., GenBank accession number NP_000313), peripherin, retinal pigment epithelium-specific protein (RPE65) (see, e.g., GenBank AAC39660; and Morimura et al. (1998) Proc. Natl. Acad. Sci. USA 95:3088), CHM (choroideremia (Rab escort protein 1)), polypeptides that cause congenital choroidal absence if they are insufficient or lost (see, e.g., Donnelly et al. (1994) Hum. Mol. Genet. 3:1017; and van Bokhoven et al. (1994)). See Hum. Mol. Genet. 3:1041; and may include Crumbs homolog 1 (CRB1), a polypeptide that, if deficient or lost, causes Leber congenital amaurosis and retinitis pigmentosa (see, for example, den Hollander et al. (1999) Nat. Genet. 23:217; and GenBank accession number CAM23328).Suitable polypeptides include those that cause color blindness when deficient or absent, such as, for example, the cone photoreceptor cGMP-gated channel subunit alpha (CNGA3) (see, e.g., GenBank accession number NP_001289; and Booij et al. (2011) Ophthalmology 118:160-167); the cone photoreceptor cGMP-gated cation channel subunit beta (CNGB3) (see, e.g., Kohl et al. (2005) Eur J Hum Genet. 13(3):302); guanine nucleotide-binding proteins (G proteins), alpha-transduction-active polypeptide 2 (GNAT2) (ACHM4); and ACHM5; as well as polypeptides that cause various forms of color blindness when deficient or absent.
[0096]
[0112] In some cases, biologics contain site-selective endonucleases that provide site-selective knockdown of gene function, for example, in this case the endonuclease knocks out an allele associated with retinal disease. For example, if the dominant allele is a retinal structural protein and / or provides normal retinal function in the wild type, and encodes a defective gene copy, then the site-selective endonuclease can target the defective allele and knock it out. In addition to knocking out a defective allele, site-selective nucleases can also be used to stimulate homologous recombination by donor DNA encoding a functional copy of the protein encoded by the defective allele. Therefore, for example, the AAV virion of the subject can be used to deliver both site-selective endonucleases that knock out the defective allele, or it can be used to deliver a functional copy of the defective allele, resulting in repair of the defective allele, thereby providing the production of a functional retinal protein (e.g., functional retinosuxin, functional RPE65, functional periferin, etc.). See, for example, Li et al. (2011) Nature 475:217. In some embodiments, the AAV virion of the subject comprises a transgene encoding a site-selective endonuclease and a heterologous nucleotide sequence encoding a functional copy of the defective allele, in which case the functional copy encodes a functional retinal protein. Examples of functional retinal proteins include retinosuxin, RPE65, retinitis pigmentosa GTPase regulator (RGPR)-interacting protein-1, periferin, periferin-2, etc. Suitable site-selective endonucleases for use include, for example, CRISPR, Zn finger nucleases (ZFNs), and TAL effector nucleases (TALENs), in which case such site-selective endonucleases do not exist in nature and are modified to target specific genes.Such site-selective nucleases can be manipulated to cleave specific locations within the genome, and the non-homologous end junction can then be repaired by inserting or removing several nucleotides. Such site-selective endonucleases (also known as "INDELs") then remove proteins from the frame, efficiently knocking out genes. See, for example, U.S. Patent Application Publication 2011 / 0301073.
[0097]
[0113] In some embodiments, cell-type-specific or tissue-specific promoters can be operably ligated to a transgene encoding a therapeutic agent of the subject, thereby selectively or preferentially producing the gene product in a particular cell type or tissue. In some embodiments, an inducible promoter will be operably ligated to the transgene sequence. In some cases, the promoter can be operably ligated to a photoreceptor-specific regulatory element (e.g., a photoreceptor-specific promoter), for example, a regulatory element that confers selective expression of an operably ligated gene in photoreceptor cells. Suitable photoreceptor-specific regulatory elements include, for example, rhodopsin promoters, rhodopsin kinase promoters (Young et al. (2003) Ophthalmol. Vis. Sci. 44:4076); beta-phosphodiesterase gene promoters (Nicoud et al. (2007) J. Gene Med. 9:1015); retinitis pigmentosa gene promoters (Nicoud et al. (2007) above); photoreceptor-retinoid-binding protein (IRBP) gene enhancers (Nicoud et al. (2007) above); and IRBP gene promoters (Yokoyama et al. (1992) Exp Eye Res. 55:225).
[0098]
[0114] In some embodiments, biologics delivered by a modified AAV of the subject can act to inhibit angiogenesis. In certain preferred embodiments, biologics delivered by a modified AAV of the subject may function to inhibit the activity of one or more mammalian VEGF proteins selected from the group consisting of VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PDGF. In a particularly preferred embodiment, biologics delivered by an AAV variant of the subject inhibit the activity of VEGF-A. VEGF-A has nine isoforms produced by alternative splicing, the most physiologically relevant being VEGF165. VEGF-A levels have been found to be elevated in the vitreous humor of patients with exudative age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Gene products (plural) that inhibit VEGF-A activity in the eye and are therefore effective in treating patients with high vitreous VEGF-A levels include, but are not limited to, aflibercept, ranibizumab, brolucizumab, bevacizumab, and soluble fms-like tyrosine kinase 1 (sFLTl) (GenBank accession number U01134). In some embodiments, an infectious AAV virion is provided comprising (i) a variant AAV capsid protein as described herein and (ii) a transgene comprising a VEGF inhibitor. In some embodiments, the transgene comprises multiple sequences, each encoding a different VEGF-A inhibitor. In some embodiments, the transgene may be aflibercept.
[0099]
[0115] The compositions and methods provided herein may be sufficient to increase the delivery of the subject's transgene by at least about 3%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or up to 100% compared to otherwise equivalent unmodified AAVs, e.g., AAV capsids. In some cases, the modification increases the delivery of the subject's transgene by at least 1, 6, 11, 16, 21, 26, 31, 36, 41, 46, 51, 56, 61, 66, 71, 76, 81, 86, 91, 96, 101, 106, 111, 116, 121, 126, 131, 136, 141, 146, 151, 156, and 161 times compared to an equivalent unmodified AAV, e.g., an AAV capsid. It may be sufficient to increase it by 166 times, 171 times, 176 times, 181 times, 186 times, 191 times, 196 times, 201 times, 206 times, 211 times, 216 times, 221 times, 226 times, 231 times, 236 times, 241 times, 246 times, 251 times, 256 times, 261 times, 266 times, 271 times, 276 times, 281 times, 286 times, 291 times, 296 times, 301 times, 306 times, 311 times, 316 times, 321 times, 326 times, 331 times, 336 times, 341 times, 346 times, or 350 times.
[0100]
[0116] The subject AAV virion may exhibit at least 1-fold, 6-fold, 10-fold, 15-fold, 20-fold, 25-fold, at least 50-fold, or more increased infectivity of retinal cells (photoreceptors, ganglion cells, RPE cells, amacrine cells, horizontal cells, Müller cells, etc.) compared to the infectivity of retinal cells (photoreceptors, ganglion cells, RPE cells, amacrine cells, horizontal cells, Müller cells, etc.) by AAV virions containing equivalent WT AAV capsid proteins.
[0101]
[0117] In some embodiments, modified compositions of the subject, e.g., AAV virion, selectively infect retinal cells with 10, 15, 20, 25, 50, or more than 50 times the specificity of non-retinal cells, e.g., cells from the outside of the eye. For example, in some embodiments, the AAV virion of the subject selectively infects retinal cells, and for example, the manipulated AAV virion of the subject infects photoreceptor cells with 10, 15, 20, 25, 50, or more than 50 times the specificity of non-retinal cells, e.g., cells from the outside of the eye. In some embodiments, the AAV virion of the subject exhibits at least 10, at least 15, at least 20, at least 25, at least 50, or more than 50 times the infectivity of retinal cells compared to the infectivity of retinal cells by AAV virion otherwise containing equivalent AAV capsid protein. In some cases, the AAV virion of the subject exhibits at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more increased infectivity of retinal cells when administered by intravitreous injection, compared to the infectivity of retinal cells with an otherwise equivalent unmodified AAV virion containing the corresponding parent AAV capsid protein. In one embodiment, the AAV virion of the subject exhibits at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more increased infectivity of photoreceptor (rod or cone) cells compared to the infectivity of photoreceptor cells with an AAV virion containing the corresponding parent AAV capsid protein. In some embodiments, the subject AAV virion exhibits at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 50-fold, or more increased infectivity of photoreceptor (rod or cone) cells when administered by intravitreous injection, compared to the infectivity of photoreceptor cells by an AAV virion containing the corresponding parent AAV capsid protein when administered by intravitreous injection.In some embodiments, the subject AAV virion exhibits an increased RGC infectivity of at least 10 times, at least 15 times, at least 20 times, at least 25 times, at least 50 times, or more than 50 times, compared to the infectivity of RGC by an AAV virion containing the corresponding parent AAV capsid protein. In some embodiments, when administered by intravitreal injection, the subject AAV virion exhibits an increased RGC infectivity of at least 10 times, at least 15 times, at least 20 times, at least 25 times, at least 50 times, or more than 50 times, compared to the infectivity of RGC by an AAV virion containing the corresponding parent AAV capsid protein.
[0102]
[0118] In one embodiment, transduction, infectivity, and / or tropism are detected by identifying the presence of the transgene in infected cells in vitro. Increases in transduction of retinal cells, such as increased transduction efficiency, more widespread transduction, or more favorable transduction, can be readily assessed in vitro or in vivo by various methods in the art for measuring gene expression. For example, AAV may be packaged by a genome containing an expression cassette with a reporter gene, e.g., a fluorescent protein, under the control of a ubiquitous or tissue-specific promoter, and the degree of transduction is assessed by detecting the fluorescent protein, e.g., by fluorescence microscopy. In another embodiment, AAV may be packaged by a genome containing a barcoded nucleic acid sequence, and the degree of transduction is assessed by detecting the nucleic acid sequence, e.g., by PCR. In yet another embodiment, AAV may be packaged by a genome containing an expression cassette with a therapeutic gene for the treatment of retinal disease, and the degree of transduction is assessed by detecting the treatment of retinal disease in affected patients administered AAV. For example, cells can be transduced using the modified capsid AAV compositions described herein, and the presence of the transgene can be identified by microscopy, flow cytometry, PCR-based assays, ELISA, histology, or any combination thereof.
[0103]
[0119] This disclosure further provides a method for delivering a transgene to an object that requires it. The method generally involves introducing a composition of the subject, such as a composition comprising a modified AAV capsid, such as, but not limited to, an AAV virion, an AAV vector, or a combination thereof, into an individual.
[0104]
[0120] Transduced cells and / or AAV virions exhibiting transduction potential, for example, can then be formulated into pharmaceutical compositions, which are described more fully below, and which are transduced to subjects by various techniques, such as intravitreous, intramuscular, intravenous, subcutaneous, and / or intraperitoneal injection.
[0105]
[0121] For in vivo delivery, the subject AAV virion can be formulated into pharmaceutical compositions and generally administered intravitreally or parenterally (e.g., by routes of administration such as intramuscular, subcutaneous, intratumoral, percutaneous, or intrathecal).
[0106]
[0122] The compositions described herein can be formulated into pharmaceutical compositions. In some embodiments, the pharmaceutical compositions can be used to treat subjects requiring treatment, such as humans or mammals. In some cases, the subject may be diagnosed with a disease, such as an eye disease. In some embodiments, the pharmaceutical composition of the subject is administered concurrently with a secondary therapy.
[0107]
[0123] Pharmaceutical compositions comprising any of the compositions described above may also be provided herein. The pharmaceutical compositions may be in unit dosage forms. In one embodiment, the pharmaceutical compositions provided herein comprise a modified AAV capsid.
[0108]
[0124] In some embodiments, the present disclosure provides a pharmaceutical composition comprising a) the AAV virion of the subject matter described above; and b) a pharmaceutically acceptable carrier, diluent, excipient, or buffer. In some embodiments, the pharmaceutically acceptable carrier, diluent, excipient, or buffer is suitable for use in humans.
[0109]
[0125] Examples of such excipients, carriers, diluents, and buffers include any drugs that can be administered without excessive toxicity. Examples of pharmaceutically acceptable excipients, though not limited to these, include liquids such as water, brine, glycerol, and ethanol. These may also include pharmaceutically acceptable salts, such as mineral salts (e.g., hydrochloride, hydrobromide, phosphate, sulfate), and salts of organic acids (e.g., acetate, propionate, malonate, benzoate). Furthermore, auxiliary substances, such as wetting agents and emulsifiers, pH buffers, etc., may also be present in such vehicles. A variety of pharmaceutically acceptable excipients are well known in the art and do not need to be described in detail herein. Pharmaceutically acceptable excipients are well described in various publications, such as A. Gennaro (2000) "Remington: The Science and Practice of Pharmacy," 20th edition, Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms and Drug Delivery Systems (1999) HC Ansel et al., eds., 7th ed., Lippincott, Williams, & Wilkins; and Handbook of Pharmaceutical Excipients (2000) AH Kibbe et al., eds., 3rd ed. Amer. Pharmaceutical Assoc.
[0110]
[0126] The pharmaceutical compositions provided herein can be used to prevent and / or treat diseases. In some embodiments, the disease is an eye disease. In some cases, the eye disease is a juvenile disease. In some cases, the eye disease is an aging disease. In some cases, the eye disease is a retinal disease. Eye diseases that can be prevented and / or treated by the pharmaceutical compositions and methods provided herein include color blindness, neovascularization-related retinal disorders such as age-related macular degeneration (AMD), exudative age-related macular degeneration (wAMD), geographic atrophy (GA), diabetic retinopathy (DR), diabetic macular edema (DME), glaucoma, Burdett-Beedle syndrome, Best's disease, congenital choroidal agenesis, Leber congenital amaurosis, Leber hereditary optic neuropathy (LHON), macular degeneration, polypoidal choroidal vasculopathy (PCV), retinitis pigmentosa, Refsum disease, Stargardt disease, Usher syndrome, X-linked retinoschisis (XLRS), hereditary retinal diseases (IRD), rod-cone dystrophy, cone-rod dystrophy, Oguchi disease, and Malattia. These include leventinese (familial dominant drusen), blue cone monochromatic color blindness, retinal vein occlusion (RVO), and uveitis macular edema (UMO). In some cases, the retinal disease is AMD. In some cases, the retinal disease is exudative AMD. In some cases, the retinal disease is atrophic AMD.Further eye diseases include acute macular optic nerve retinal disorders; Behçet's disease; choroidal neovascularization; diabetic uveitis; histoplasmosis; macular degeneration, e.g., acute macular degeneration, non-exudative age-related macular degeneration, and exudative age-related macular degeneration; edema, e.g., macular edema, cystoid macular edema, and diabetic macular edema; multifocal choroiditis; eye trauma affecting the posterior eye site or position; eye tumors; retinal disorders, e.g., central retinal vein occlusion, diabetic retinopathy (e.g., proliferative diabetic retinopathy), proliferative vitreoretinopathy (PVR), retinal artery occlusive disease, retinal detachment, uveitis; sympathetic ophthalmitis; Vogt-Koyanagi-Harada (VKH) syndrome; uveal diffusion. Diffusion; posterior segment conditions caused or affected by laser treatment of the eye; posterior segment conditions caused or affected by photodynamic therapy; photocoagulation; radiation retinopathy; epiretinal membrane disorders; branch retinal vein occlusion; anterior ischemic optic neuropathy; non-retinopathy diabetic retinal dysfunction; retinal schizophrenia; retinitis pigmentosa; glaucoma; Usher syndrome; cone-rod dystrophy; Stargardt disease (macula punctata); hereditary macular degeneration; chorioretinal degeneration; Leber congenital amaurosis; congenital constant night blindness; congenital choroidal agenesis; Burdett-Beedle syndrome; macular telangiectasia; Leber hereditary optic neuropathy; premature retinopathy; and color vision disorders, including color blindness, red blindness, green blindness, and blue-yellow blindness.
[0111]
[0127] In some cases, the subject to which the composition of the subject can be administered is one that is receiving, will receive, or will receive after the administration of a secondary therapy. Secondary therapy may include any therapy for use in the eye. In some cases, secondary therapy includes nutritional therapy, vitamins, photodynamic therapy, such as laser therapy, e.g., laser photocoagulation, Visudyne, anti-VEGF therapy, eyewear, eye drops, local anesthetics, vision correction therapy, behavioral / perceptual vision therapy, etc. In some embodiments, any of the biological products described above may be considered a secondary therapy.
[0112]
[0128] This disclosure provides a method for delivering a transgene to retinal cells in an individual, comprising the step of administering the individual the AAV virion of the subject described above. The step of delivering the transgene to retinal cells can provide a treatment for retinal diseases. Retinal cells may be photoreceptor cells, retinal ganglion cells, Müller cells, bipolar cells, amacrine cells, horizontal cells, or retinal pigment epithelial cells. In some cases, the retinal cells are photoreceptor cells, such as rod or cone cells.
[0113]
[0129] This disclosure provides a method for treating a retinal disease, comprising the step of administering an effective amount of the subject AAV virion described above to an individual in need. The subject AAV virion can be administered by intraocular injection, intravitreous injection, or by any other convenient mode or route of administration. Other convenient modes or routes of administration include, for example, intravenous or intranasal injection. When administered by intravitreous injection, the subject virion can travel through the vitreous humor, cross the internal limiting membrane (hereinafter also referred to herein as the inner limiting membrane or "ILM"; a thin, transparent, cell-free membrane on the surface of the retina that forms the boundary between the retina and the vitreous humor, formed by the end feet of astrocytes and Müller cells), and / or travel more efficiently through the layers of the retina compared to the ability of the AAV virion containing the corresponding parent AAV capsid protein.
[0114]
[0130] This disclosure also provides a method for treating a retinal disease, comprising the step of administering an effective dose of a modified AAV virion containing the transgene for the subject described above and disclosed herein to an individual in need. Those skilled in the art will be able to readily determine the effective dose of the subject virion and whether the disease has been treated by examining changes in one or more functional or anatomical parameters, such as visual acuity, visual field, electrophysiological responsiveness to light and darkness, color vision, contrast sensitivity, anatomical structure, retinal health and vascular structure, eye movements, fixation preference, and stability.
[0115]
[0131] Non-limiting methods for evaluating retinal function and its changes include assessment of visual acuity (e.g., best-corrected visual acuity [BCVA], gait, navigation, object detection, and discrimination), assessment of visual fields (e.g., static and dynamic perimetry), performance of clinical examinations (e.g., slit-lamp examination of the anterior and posterior segments), and assessment of electrophysiological responses to all wavelengths in light and darkness (e.g., all forms of electroretinography (ERG) [whole field, multifocal, and pattern], all forms of visual evoked potentials (VEP), electrooculography (EOG), color vision, dark adaptation, and / or contrast sensitivity). Non-limiting methods for assessing anatomical structures and retinal health and changes include optical coherence tomography (OCT), fundus photography, adaptive optics scanning laser ophthalmoscopic examination (AO-SLO), fluorescence and / or autofluorescence; measurement of eye movements and ocular motion (e.g., nystagmus, fixation dominance, and stability); measurement of reported outcomes (patient-reported changes in visual and non-visual induced behavior and activity, patient-reported outcomes [PRO], questionnaire-based assessment of quality of life, and measurement of daily activities and neurological function (e.g., functional magnetic resonance imaging (MRI)).
[0116]
[0132] In some embodiments, an effective dose of the subject rAAV virion results in a reduction in the rate of decline of retinal function, anatomical integrity, or retinal health, e.g., a 2x, 3x, 4x, or 5x reduction in the rate of decline, or more, resulting in a reduction in disease progression, e.g., a 10x reduction in the rate of decline, or more, resulting in a reduction in disease progression. In some embodiments, an effective dose of the subject rAAV virion results in gains in visual function, retinal function, retinal anatomy or health, and / or improvements in eye movement, and / or improvements in neurological function, e.g., a 2x, 3x, 4x, or 5x improvement in retinal function, retinal anatomy or health, and / or improvements in eye movement, e.g., a 10x improvement in retinal function, retinal anatomy or health, and / or improvements in eye movement. As will be readily understood by those skilled in the art, the dose required to achieve the desired therapeutic effect is typically 1 × 10⁻⁶ 8 From approximately 1 x 10 15 It is a recombinant billion in the range of 1 × 10, which is typically defined by those skilled in the art. 8 From approximately 1 x 10 15 This is called a "vector genome".
[0117]
[0133] In some embodiments, the compositions provided herein, such as pharmaceutical compositions, are administered to subjects requiring them. In some cases, the administration involves approximately 0.5 × 10⁻¹⁶ vectors. 9 vg, 1.0 × 10 9 vg, 1.0 × 10 10 , 1.0 × 10 11 vg, 3.0×10 11 vg, 6×10 11 vg, 8.0×10 11 vg, 1.0 × 10 12 vg, 1.0 × 10 13 vg, 1.0 × 10 14 vg, 1.0 × 10 15 vg, 1.5×10 15The process includes delivering a dosage of vg AAV vector. For example, in the case of in vivo injection, i.e., direct injection into the eye, the therapeutically effective dose is approximately 10 6 From about 10 15 AAV billion of subjects of the order of order, for example, about 10 8 from 10 12 This can be an order of manipulated AAV virions. In the case of in vitro transduction, the effective amount of manipulated AAV virions delivered to the cells is approximately 10 8 From about 10 13 The manipulated AAV virion would be of the order of magnitude. Other effective dosages can be readily established by those skilled in the art through standard trials to establish dose-response curves.
[0118]
[0134] The administration can be repeated at any time. In some embodiments, the administration process may be carried out twice daily, every other day, twice a week, every other month, every three months, once a month, every other month, every six months, annually, or twice a year.
[0119]
[0135] The drug administration may be a single-dose schedule or a multi-dose schedule. Furthermore, the subject may be administered in multiple doses as needed. Those skilled in the art can easily determine the appropriate number of doses. In some embodiments, the pharmaceutical composition is administered by intravitreous injection, subretinal injection, microinjection, or ocular injection.
[0120]
[0136] In some embodiments, a subject can be screened for mutations by genetic testing before, during, and / or after administration of the pharmaceutical composition provided herein. Relevant genes that can be screened for mutations include RPE65, CRB1, AIPL1, CFH, or RPGRIP.
[0121]
[0137] Kits comprising any of the compositions provided herein are also provided: a) a modified adeno-associated virus (AAV) capsid of the subject; b) a vector of the subject; or c) a container comprising an engineered virion of the subject. In some embodiments, the container is a vial, syringe, or needle. In some cases, the container is configured for ocular delivery.
[0122]
[0138] The kit may contain preferably equally divided compositions. The components of the kit may be packaged either in an aqueous medium or in a lyophilized form. The kit's container means will generally include at least one vial, test tube, flask, bottle, syringe, or other container means in which the components can be placed, preferably preferably equally divided. If the kit contains two or more components, the kit will generally also include a second, third, or other additional container in which additional components can be placed separately. However, various combinations of components may be contained in vials. The kit will typically also include means for tightly confining and containing the components for commercial sale. Such containers may include syringes or blow-molded plastic containers in which the desired vials are held.
[0123]
[0139] In some cases, packaged products containing the compositions described herein may be appropriately labeled. In some cases, the pharmaceutical compositions described herein may be manufactured in accordance with Good Manufacturing Practices (cGMP) and labeling regulations. In some cases, the pharmaceutical compositions disclosed herein may be sterile. [Examples]
[0124] Example 1 Modified AAV capsid design
[0140] Decanoyl-L-peptidyl fragments (10 amino acid residues) were partially randomized for the initial analysis. The starting amino acid sequence of the initial peptide fragment is provided as formula 1:X0-X1-X2-X1-X3-X1-X1-X4 (SEQ ID NO: 108), where X0 is valine (V), isoleucine (I), leucine (L), phenylalanine (F), tryptophan (W), tyrosine (Y), or methionine (M); X1 is alanine (A), asparagine (N), glutamine (Q), serine (S), threonine (T), glutamic acid (E), aspartic acid (D), lysine (K), arginine (R), or histidine (H); X2 is V, I, L, or M; X3 is E, S, or Q; X4 is K, R, E, or A; and X5 is proline (P) or R.
[0125]
[0141] The modified peptides were partially inserted into loops 3 and / or 4 of the AAV2 (or other suitable AAV serotype as provided herein) viral protein (VP1) and analyzed using a publicly available structural modeling system. Three-dimensional structures with similar phenotypes and / or structural appearances to the wild-type loop structure of the unmodified AAV2 capsid were selected for biological evaluation. Table 2 provides exemplary AAV2 Rep and modified AAV2 capsid regions.
[0126] [Table 2-1]
[0127] [Table 2-2]
[0128] [Table 2-3]
[0129] [Table 2-4]
[0130] [Table 2-5]
[0131] [Table 2-6]
[0132] [Table 2-7]
[0133] [Table 2-8]
[0134] [Table 2-9]
[0135] [Table 2-10]
[0136] [Table 2-11]
[0137] Example 2 Generation of modified AAV capsids Construction of a pFB shuttle plasmid containing AAV2 Rep and modified AAV2 capsid genes.
[0142] Using PCR, the desired mutant peptide was inserted into the AAV2 capsid gene of the V449 plasmid backbone. Briefly, the plasmid V449-pFB-inCap2-inRep-kozak-hr2 was cleaved with the restriction enzymes BsiWI and XbaI (New England Biolabs, Ipswich, MA) to isolate a 9113 bp backbone fragment. The 5' PCR fragment and 3' PCR fragment containing the DNA sequence of the desired mutant peptide were amplified using V449-pFB-inCap2-inRep-kozak-hr2 as a template, and then ligated together by a second PCR to form a single PCR fragment. The ligated PCR fragments were then cloned into the BsiWI and XbaI sites of V449-pFB-inCap2-inRep-kozak-hr2 using the NEBuilder HiFi DNA Assembly Kit (New England Biolabs) to produce the desired clone. However, clone V471-pFB-inCap2-452_587RtoK-inRep-kozak-hr2 was generated using V467-pFB-inCap2-587RtoK-inRep-kozak-hr2 as a template for the PCR reaction and a backbone for HiFi assembly. The resulting clone was validated by restriction enzyme digestion, and the mutation site was confirmed by DNA sequencing analysis. The clone numbers and PCR primers are provided in Table 3.
[0138] [Table 3]
[0139]
[0143] Table 4 provides the sequences of primers used for PCR reactions and DNA sequencing analysis.
[0140] [Table 4-1]
[0141] [Table 4-2]
[0142] Production of recombinant baculoviruses
[0144] Recombinant baculoviruses were generated using a Bac-to-Bac baculovirus expression system according to the manufacturer's instructions for use (Invitrogen, Carlsbad, CA). Briefly, each pFB shuttle plasmid containing the target gene as previously described was diluted to 1 ng / μL in TE buffer, and 2 ng of each DNA was mixed with 20 μL of Δcath-DH10Bac competent bacteria (Virovek, Hayward, CA) containing a bacmid DNA molecule lacking the cathepsin gene. The mixture was incubated on ice for 30 minutes, followed by a heat shock at 42°C for 30 seconds. After incubation on ice for 2 minutes, the bacteria were cultured at 37°C for 4 hours and harvested. The resulting cells were then plated onto agar plates containing 50 μg / mL kanamycin, 7 μg / mL gentamicin, 10 μg / mL tetracycline, 40 μg / mL IPTG, and 100 μg / mL X-gal. After incubation at 37°C for 48 hours, white colonies containing recombinant bacmid DNA were collected, and the miniprep bacmid DNA was purified under sterile conditions. Approximately 5 μg of each bacmid DNA and 10 μL of GeneJet reagent (SignaGen Laboratories, Fredrick, MD) were each diluted in 100 μL of ESFAF medium (Expression Systems, Davis, CA), and then mixed together for approximately 30 minutes to form transfection mixtures. Sf9 cells were plated in 6-well plates at a rate of 1.5e+6 cells / well in 2 mL of ESFAF medium at 28°C for approximately 30 minutes. After removing the old medium from the Sf9 cells, each transfection mixture was diluted in 800 μL of ESFAF medium and then added to the Sf9 cells. After incubation overnight at 28°C, an additional 1 mL of ESFAF medium was added to each well containing the Sf9 cells. After a total of four days of incubation, the recombinant baculovirus was collected without cells and amplified to a ratio of 1:200 to produce a sufficient amount of recombinant baculovirus for use in the AAV production process.
[0143]
[0145] Sf9 cell cultures were maintained in Corning bottles in ESF AF medium (Expression Systems) containing 100 units / mL of penicillin and 100 ug / mL of streptomycin (Thermo Fisher Scientific, Pleasanton, CA), with gentle agitation at 150 rpm and 28°C. Once the cells had grown to approximately 1e+7 cells / mL, they were divided 1:4 into fresh bottles of medium for continuous culture.
[0144] Example 3 AAV production and purification
[0146] Sf9 cells were co-infected for AAV production using recombinant baculoviruses containing the AAV2 Rep gene, the mutant AAV2 capsid gene, and CMV-GFP, respectively. Briefly, 10 moi of rBV containing the Rep and Cap genes, and 5 moi of rBV containing CMV-GFP, were used to co-infect Sf9 cell lines at a density of approximately 5e+6 cells / mL in 50% fresh ESFAF medium at 28°C for 3 days at a shaking incubator at a shaking rate of 180 rpm. At the end of infection, the cell pellet was collected by centrifugation at 3,000 rpm for 10 minutes. The cells were lysed in Sf9 lysis buffer containing 50 mM Tris-HCl, pH 8.0, 2 mM MgCl2, 1% sarcosyl, 1% Triton X-100, and 125 units / mL benzonase by vigorous vortexing followed by shaking at 350 rpm for 1 hour at 37°C. At the end of shaking, the salt concentration was adjusted to 500 mM, and the solubilized solution was clarified by centrifugation at 8,000 rpm at 4°C for 20 minutes. The clarified solubilized solution was transferred to ultraclear centrifuge tubes for SW28 swing bucket rotors containing 5 mL of 1.50 g / cc and 10 mL of 1.30 g / cc of cesium chloride solution. After centrifugation at 28,000 rpm at 15°C for approximately 18 hours, the AAV bands were collected with a syringe and transferred to ultraclear centrifuge tubes for 70ti centrifuge rotors. The centrifuge tubes were filled with 1.38 g / cc of cesium chloride solution and heat-sealed. The AAV samples were subjected to a second round of ultracentrifugation at 65,000 rpm at 15°C for approximately 18 hours, and the AAV bands were collected with a syringe. The purified AAV samples were buffer-exchanged with PBS buffer containing 0.001% Pluronic® F-68 and filtered and sterilized using a 0.22 μm syringe filter. The sterilized AAV samples were stored at 4°C for up to one month, and then transferred to -80°C for long-term storage. AAV titers were determined by real-time PCR using a QuantStudio 7 Flex real-time PCR system (Invitrogen). In some embodiments, AAV titers can be determined by a TCID50 (50% tissue culture infectious dose) AAV vector infectivity titer assay.The TCID50 AAV titer assay can be performed by first culturing transducible cells in complete medium containing DMEM supplemented with 10% FBS and 1% penicillin / streptomycin solution. Cells are cultured in a 96-well plate and then transduced with one of the modified AAVs described herein. Transduction may involve diluting the adenovirus to a final concentration of 3.2e+8 adenovirus particles per milliliter. The modified AAV vector may be diluted by serial dilutions for the titer assay. Cells may then be transduced with different serially diluted modified AAV vectors. DNA may be extracted from the transduced cells. The extracted DNA may then be assayed under Taqman thermocycling conditions using a Taqman probe to obtain an amplified signal. The logarithmic phase of the amplified signal may correspond to the concentrations obtained from the serial dilutions of the modified AAV vector.
[0145] gel electrophoresis
[0147] SDS-PAGE electrophoresis was performed to visualize the AAV capsid protein. The AAV sample was mixed with SDS gel loading buffer, heated at 95°C for 5 minutes, loaded with 1e+11vg / lane of AAV vector, and electrophoresis was performed at 100V until the loading dye reached the bottom of the gel. The AAV capsid protein was stained with the SimplyBlue SafeStain kit (Thermo Fisher Scientific). Gel images were recorded using a BIO-RAD molecular imager Gel-Doc XR+ (Bio-Rad, Hercules, CA). Agarose gel electrophoresis was performed to visualize the AAV genome. The AAV sample was diluted in PBS buffer containing 0.1% SDS and heated at 80°C for 10 minutes. After switching off the heater and allowing the mixture to cool slowly to room temperature, 2e+11vg / lane of AAV vector was loaded onto a 1% agarose gel in TAE buffer containing SYBR Safe DNA gel stain (Invitrogen, Carlsbad, CA), and electrophoresis was performed at 100V for 1 hour. Images were recorded using a BIO-RAD molecular imager.
[0146] Cell culture and in vitro transduction of ARPE19 and HEK293
[0148] ARPE-19 (ATCC CRL2302) is a suitable model of RPE cells because it expresses typical RPE markers such as cellular retinaldehyde-binding protein (CRALBP) and RPE-specific 65kDa protein (RPE65). Cells were maintained in Dulbecco's Modified Eagle Medium / F-12 nutrient medium (DMEM / F-12; Gibco BRL, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (Gibco BRL) and 1% penicillin-streptomycin. Cells were maintained in an incubator in a humidified atmosphere at 37°C and 5% CO2 and passaged every 3-4 days using 0.25% trypsin-EDTA (Life Technologies, Carlsbad, CA, USA). For experiments, RPE cells within the first 10 passages were selected and placed in appropriate culture plates.
[0147]
[0149] HEK293 cells were obtained from ATCC (CRL-1573; Manassas, VA, USA) and cultured in high-glucose Dulbecco's modified Eagle medium (DMEM; Gibco BRL, Carlsbad, CA, USA). The medium was supplemented with 10% fetal bovine serum (Gibco BRL) and 1% penicillin-streptomycin. The cells were maintained in an incubator under a humidified atmosphere at 37°C and 5% CO2, and subcultured every 3-4 days using 0.25% trypsin-EDTA (Life Technologies, Carlsbad, CA, USA).
[0148] Example 4 In vitro transduction assay of AAV2 capsid variant
[0150] ARPE-19 or HEK293 cells were seeded in 12-well plates at 60% confluence and grown to subconfluence. Cells were nutrient-supplied 2–4 hours prior to infection, the medium was changed to 2% FBS, and the cells were exposed to 1 ml of wild-type or capsid-modified AAV2-CMV-GFP for 1 hour. Complete medium was then added, and incubation was continued for 3–7 days. All infections were performed using the same number of vg (2.0e+13 cells), resulting in an estimated MOI of 1.0e+5 vg / cell. GFP expression was analyzed using an inverted fluorescence microscope with a monochromatic DP80 camera (Olympus, Center Valley, PA, USA). All images were acquired using digiCAMControl at the same unsaturated exposure time.
[0149]
[0151] Transduction of ARPE-19 cells, HEK293 cells, or any other cell type with any one of the modified AAV vectors may involve the use of the following materials and apparatus: Purification of AAV2.N54.VEGF-Trap (AMI054-AMI120-scCMV-aflibercept-GCRS), also known as AVMX-110, followed by buffer exchange to formulation buffer (concentration of 9.23e+12vg / mL, stored at -80°C); thawing of human fetal kidney cells (HEK293, ATCC, catalog no. CRL-1573) and routine passage number description; and cell culture and transduction using EMEM medium (ATCC, catalog no. 30-2003) containing 10% FBS (ATCC, catalog no. 30-2020). Store the culture medium at 4°C; trypsin-EDTA (0.25%), phenol red (Thermofisher Scientific, catalog no. 25200056); 1× PBS (phosphate-buffered saline): diluted to 10× PBS (Fisher Scientific, Hyclone, catalog no. SH3025802) with culture-grade sterile water (Fisher Scientific, Hyclone, catalog no. SH30529LS). Store at 4°C; 6-well culture plate (Greiner bio-one / Cellstar, catalog no. 657160); biosafety cabinet (Labconco Purifier Class II); incubator set to 37°C and 5% CO2 (Therma forma, Series II water-jacketed CO2 incubator); and V226-AMI067 (positive control, V226-pFB-inCap2-7m8-AMI067-scCMV-aflibercept-GC).Transduction procedures may include: culturing HEK293 cells (or any other cell type) in a T-75 flask containing EMEM medium supplemented with 10% FBS, keeping records of passage number and cell viability; removing the flask from the incubator, removing the old medium, and rinsing the flask with 10 mL of 1×PBS; discarding the 1×PBS, adding 0.5 mL of trypsin solution, and letting the flask stand for 1-2 minutes; adding 10x v / v volume (5 mL) of serum-containing medium to neutralize the trypsin and dissociate the cells from the culture flask; transferring the cell suspension to a 15 mL tube and centrifuging at 300 g for 3 minutes; adding 1 mL of EMEM medium to resuspend the cells; adjusting the cell count to 1.0 e+0 6 / mL by counting the cells and adding medium; adding 1 mL to each well of a 6-well plate; returning the plate to the incubator and allowing the cells to adhere to the bottom of the wells for 24 hours; after 24 hours, MOI Prepare a total of 1.0e+11 (=1.0e+06 * 100,000) viral particles / mL of AAV2.N54.VEGF-Trap and V226-AMI067 (positive control) in fresh medium; add 1 mL of AAV2.N54.VEGF-Trap, or positive control, or fresh medium (negative control) in two wells; return the 6-well plate to the incubator; after another 24 hours, replace the medium in all wells with 1 mL / well of fresh medium and return the plate to the incubator; on day 4 after transduction, collect the supernatant from each well of the plate and dispense it into 1.5 mL sterile Eppendorf tubes at 300-500 μL / tube depending on the requirements of the assay; quantify the VEGF-Trap concentration in each collected supernatant using VEGF-Trap ELISA, or store the supernatant at -80°C. Table 5 shows exemplary studies of AAV infectivity demonstrating that a modified AAV vector (modified AAV2.N54) exhibits increased infectivity compared to wild-type AAV2.
[0150] [Table 5]
[0151] Example 5 Modification of AAV2 orientation to the retina
[0152] To study the ability of AAV2 as a scaffold for peptide display and rAAV2 vector production, peptides with lengths of 3–10 aa were displayed on AAV2. This range is well-tolerated and may be sufficient for capsid retargeting. Regions within the cap gene were selected for in-frame oligonucleotide insertions, which have the potential for displaying encoded peptides at protruding locations on the assembled particle, i.e., in loops 3 and 4. As shown in Figure 1, peptide insertions in rAAV2 are located at the tip of either loop 3 or loop 4, and unlike in parental AAV2, they extend further outward beyond loop 3 or loop 4 (Figure 1, right panel). A surface view of the AAV2 structure shows that the insertions are present in all 60 VP subunits.
[0152]
[0153] As shown in Table 6, a series of AAV2 vectors with modified capsids were successfully produced and purified. As shown in Figure 2, SDS-PAGE showed that after two rounds of ultracentrifugation with a cesium chloride density gradient, the AAV2 vectors were purer than 98%, with only trace amounts of contaminating protein. Table 7 shows the expression of GFP (delivered to the cells via the AAV vectors described herein) in HEK293 cells or ARPE19 cells when transduced with the modified AAV vectors described herein. Table 7 shows, in order of appearance, SEQ ID NOs. 110-113, 111, 114-126, 118, 117, and 127-128, respectively.
[0153] [Table 6]
[0154] [Table 7]
[0155] Example 6 Effect of modified AAV2 capsid variants on transduction efficiency in human cell lines
[0154] The transduction efficiency or infectivity of AAV2 was determined using HEK293 cells and ARPE-19 (a spontaneously generated retinal pigment epithelial (RPE) cell line derived from the eye of a 19-year-old male). The transduction efficiency of all modified capsid variants was tested in both HEK293 and ARPE-19 cells. As shown in Figure 3A, the GFP expression levels in both HEK293 and ARPE-19 cells showed that the AAV2-V467 variant was the most efficient, followed by the AAV2-V471 and AAV2-V466 variants. AAV2 variants with a single mutation or combination of mutations at the R585 or R588 position of AAV2 were unable to transduce cells (Figure 3B). Insertion of other peptides in loop 3 or loop 4 of the AAV2 capsid dramatically reduced its transgene expression.
[0156]
[0155] VEGF-Trap can be measured using the ELISA protocol described herein. In some embodiments, the ELISA protocol utilizes the following materials and equipment: VEGF-trap; 100 μL / vial of AAV-2-VEGF-trap stored in PBS at -80°C (concentration of 4.56 mg / mL as determined by a commercially available ELISA); VEGF: 100 μg / mL; antigen expressed and purified in HEK293 cells (GeneScript, catalog no. Z03073); goat anti-human IgG Fc (biotin) serum adsorbed (Abcam, catalog no. ab98618); HRP-streptavidin conjugate (Abcam, catalog no. ab7403); TMB substrate: 1-Step™ Ultra TMB-ELISA substrate solution (ThermoFisher, catalog no. 34028); 96-well microplate reader (Molecular Device: VERSAmax tunable microplate reader; Coating buffer: 3.7g sodium bicarbonate (NaHCO3) and 0.64g sodium carbonate (Na2CO3); 1L Milli-Q water, pH 9.60, storage conditions: RT (room temperature), 1 month; 1×PBS (phosphate buffered saline): 8.0g sodium chloride, 1.3g disodium phosphate, 0.2g monosodium phosphate, and 1.0L Milli-Q water, pH 7.4, storage conditions: RT, 1 year; Washing buffer (PBST): 1× phosphate buffered saline, 0.1% Tween 20 (v / v), storage conditions: RT, expiration date 30 days from preparation date; Blocking buffer (BB): 0.1% Tween 1x phosphate-buffered saline (PBS) containing 20 (v / v) and 1% casein, stored at 4°C for 30 days from the date of preparation; dilution buffer (DB): same as blocking buffer; stop solution for TMB substrate (Abcam, catalog no. ab171529); quality control sample: VEGF-trap standard (6 ng / mL) from a commercially available aflibercept ELISA kit; and a 96-well microplate.
[0157]
[0156] The ELISA protocol may include the following steps: Dilute VEGF (100 μg / mL) stock to 0.1 μg / mL with coating buffer (10 μL of VEGF stock per 10 mL of coating buffer); Add 100 μL / well of the coating antigen to a 96-well microplate, cover the plate, and incubate at 2-8°C for approximately 12 hours or overnight; Discard the coating antigen and wash the plate three times with 300 μL / well of PBS-T wash buffer; Add 300 μL / well of blocking buffer, cover the plate, and incubate at 37±1°C for 120 minutes; Add 12.5 ng of VEGF-trap standard (4.56 mg / mL) in dilution buffer as follows: Dilute to / mL: Dilute 4.56 mg / mL 456-fold to 10 μg / mL, 10 μg / mL 10-fold to 1 μg / mL, and 1 μg / mL 10-fold to 100 ng / mL; Add 100 μL of the 100 ng / mL solution to 700 μL of dilution buffer, which is the first standard point of 12.5 ng / mL; Prepare the remainder of the VEGF-trap standard in two sets using a 1:2 step dilution scheme; Transfer the diluted standard samples, quality control samples, and unknown samples to plates in two sets, 100 μL per well for each dilution; Cover the plates and incubate them at 37±1°C for 60 minutes; Discard the reaction mixture in the plates and wash six times with 300 μL / well of wash buffer; Add the goat anti-human IgG Fc (biotin) serum adsorbed to dilution buffer (0.Dilute 0.125 μg / mL with dilution buffer to 1:40,000 and add 100 μL / well; cover the plate and incubate at 37±1°C for 60 minutes; discard the reaction mix and wash the plate 6 times with 300 μL / well wash buffer; dilute streptavidin-HRP with dilution buffer to 1:40,000 and add 100 μL / well; cover the plate and incubate at 37±1°C for 60 minutes; discard the reaction mixture in the plate and wash 6 times with 300 μL / well wash buffer; rinse the plate once with 1×PBS and remove any remaining Tween Remove component 20; add TMB substrate at 100 μL / well, cover the plate, and incubate at 37±1°C for 15 minutes; stop the reaction by adding 100 μL / well of stop solution; and read the plate using a microplate reader with a 450 nm wavelength filter and a 600 nm reference wavelength.
[0158]
[0157] Figures 3C and 3D show the expression of the VEGF-Trap gene mediated by VP1-AMI054 modified AAV1, AAV2, and AAV6: modified AAV1 including the insertion of the LALGQTTKPA exogenous polypeptide (SEQ ID NO: 14) after amino acid residue 588 (asparagine, N); modified AAV2 including the S588 insertion of the LALGQTTKPA exogenous polypeptide (SEQ ID NO: 14) after amino acid residue 588 (serine, S); and modified AAV6 including the S588 insertion of the LALGQTTKPA exogenous polypeptide (SEQ ID NO: 14) after amino acid residue 588 (serine, S). Figure 3C shows VEGF-Trap expression in HEK293 cells transduced with modified AAV1, AAV2, or AAV6. Figure 3D shows VEGF-Trap expression in ARPE-19 cells transduced with modified AAV1, AAV2, or AAV6.
[0159] Example 7 Mouse research
[0158] Animals will be allowed to acclimate to the research environment for a minimum of three days. Upon completion of the acclimatization period, each animal will be physically examined by an animal specialist to determine its suitability for participation in the study. Examinations will include, but are not limited to, skin and ear, eyes, abdomen, behavior, and overall condition. Animals determined to be in good health will be released into the study.
[0160]
[0159] Animals are randomly assigned to study groups according to facility standard operating procedures (SOPs). Animals are uniquely identified by their corresponding cage card number, ear punch, and number. Tables 8 and 9 show the test parameters and diets for the mouse study.
[0161] [Table 8]
[0162] [Table 9]
[0163] Administration scheme
[0160] On day 0 prior to injection, mice were administered buprenorphine 0.01-0.05 mg / kg SQ. Topical mydriatics (1.0% tropicamide HCl and 2.5% phenylephrine HCl) were applied at least 15 minutes before injection. The animals were sedated for intravitreal injection, and one drop of 0.5% propalacaine HCl was applied to both eyes. Alternatively, the mice could be anesthetized with inhaled isoflurane. The conjunctiva was gently grasped with Dumont #4 forceps, and the injection was administered using a 33G needle and Hamilton Syringe. After dispensing the contents of the syringe, the needle was slowly withdrawn. After the injection procedure, one drop ofloxacin eye drops was applied topically to the surface of the eyeball along with an ophthalmic lubricant.
[0164] parameter
[0161] With particular attention paid to the eyes, observations were made from the side of the cage, and mortality and morbidity assessments were performed once daily. Ocular examinations were performed using a slit-lamp biomicroscope to evaluate the surface morphology of the eyeball at the time points indicated herein. Both color and cobalt blue (EGFP-expressing) fundus imaging were performed on both eyes of all animals at the time points indicated in the experimental design. Animals were locally administered a cocktail of tropicamide (1.0%) and phenylephrine (2.5%) to dilate and protrude the eyes, and a local ophthalmic anesthetic (0.5% propalacaine or similar) was applied to the eyes. Cobalt blue photographs were taken following color fundus photography. After the final imaging procedure on day 28, animals were euthanized by carbon dioxide asphyxiation, and death was confirmed by cervical dislocation or thoracotomy.
[0165] Ocular tissue collection and processing
[0162] After the final vivisection imaging procedure, the eyeballs were removed and immediately fixed in 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) at room temperature for 4 hours (frozen section analysis) or 30 minutes (flat mount analysis). Eyes designated for flat mount analysis were rinsed with 1×PBS and stored at 4°C until dissection. Eyes designated for frozen section analysis were washed with PBS and stored at 4°C until embedding.
[0166]
[0163] Frozen section analysis: Immediately embed the eyes in 3% agarose / 5% sucrose and immerse overnight in 30% sucrose at 4°C, or store in 1×PBS until embedding the following day. Section the eye tissue and process for immunohistochemical examination. Stain the slides designated for immunohistochemical examination with antibodies against rhodopsin, RPE65, and GFP, in parallel with DAPI for nuclear localization. Secondary antibodies may include: donkey anti-mouse Cy3 (rhodopsin), donkey anti-rabbit Cy5 (RPE65), and donkey anti-chicken Cy2 (GFP).
[0167]
[0164] Flat-mount analysis of the eyeball: Using a surgical microscope, irrelevant tissue was excised from the eye, and the anterior, lens, and vitreous humor were removed. The eye cups were placed in cold methanol for 30 minutes, then rinsed three times with cold PBS for 15 minutes each. The eye cups were placed in cold ICC containing 4',6-diamidino-2-phenylindole (DAPI; nuclear stain) and three combinations of the following antibodies: anti-laminin (1 / 1,000) labeling the internal limiting membrane, anti-rhodopsin clone 4D2 (1 / 500) labeling the rods, anti-glutamine synthetase clone GS-6 (1 / 1,500) labeling Mueller cells, and PNA lectin (1 / 40) labeling the cones. The eye cups were incubated at 4°C for 4 hours with gentle rotation and washed with cold ICC buffer. After staining, the optic cup was fixed in 4% PFA for 5 minutes, then rinsed once with 1×PBS. The scleral-choroidal / RPE complex was removed from the retina using sharp curved scissors. The retina was flat-mounted, covered, and sealed. Two-dimensional (2D) fluorescence microscopy images were acquired, digitized, and analyzed using Image ProPlus or CellSens (Olympus) software, with post-acquisition analysis performed using ImageJ or CellSens software (Figure 4).
[0168]
[0165] Frozen Section Analysis: Frozen sections (14 μm thick) were prepared for immunohistochemical examination. Each slide designated for immunohistochemical examination was stained with the following three different cocktails containing antibodies against GFP and different markers of the retinal cell layer: Cocktail 1) GFP, rhodopsin, and laminin; 2) GFP, RPE65, and PNA lectin; 3) GFP, glutamate synthetase GS-6, and phalloidin. The results are shown in Figure 5. Graphs of GFP expression across all three antibody cocktails and imaging of all eyes are shown in Figure 6.
[0169]
[0166] Figures 7 to 11 and Tables 9 to 11 show in vivo imaging of mouse eyes administered with either wild-type (wt) AAV vector or the modified AAV2 vector described herein. Figure 7 shows fundus images and IHC staining of mouse eyes administered with wild-type AAV vector. wt AAV2-GFP did not result in sufficient GFP expression, as shown in both fundus imaging and IHC sections. Figure 8 shows in vivo fundus imaging and IHC staining of eyes in which the modified AAV2 described herein (AAV2-AMI053-GFP, which includes modified AAV2 having LKLGQTTKPA (SEQ ID NO: 13) inserted after amino acid residue 587) was administered to mouse eyes via the IVT pathway. The modified AAV2 showed GFP expression in fundus imaging and IHC sections, and the GFP signal was detected in multiple layers of cells. Figure 9 shows in vivo fundus imaging and IHC staining of the eye, in which the modified AAV2 described herein (AAV2-AMI054-GFP, which includes modified AAV2 having LALGQTTKPA (SEQ ID NO: 14) inserted after amino acid residue 587) was administered to the eye of a mouse via the IVT route. The modified AAV2 showed GFP expression in fundus imaging and IHC sections, and the GFP signal was detected in multiple layers of cells. Figure 10 shows in vivo fundus imaging and IHC staining of the eye, in which the modified AAV2 described herein (AAV2-V466-GFP, which includes modified AAV2 having LALGETTRPA (SEQ ID NO: 6) inserted after amino acid residue 453) was administered to the eye of a mouse via the IVT route. The modified AAV2 showed GFP expression in fundus imaging and IHC sections, and the GFP signal was detected in multiple layers of cells. Table 10 shows fundus images of mice 25 to 29 days after AAV2-VP1-GFP IVT injection.
[0170] [Table 10]
[0171]
[0167] Figure 11 shows the AAV retinal transduction index (RCTI) indicating AAV transduction in different optic nerve fiber layers of eyes transduced with either wild-type (wt) or modified AAV as described herein. The RCTI was calculated from the color intensity score of cell layers luminescent by the vector administered via the intravitreous pathway (i.e., AAV2-AMI053-GFP propagated across the internal limiting membrane (ILM) of the vitreous structure and transduced various cells via binding to receptors on the cells). The appearance of a GFP signal indicates that the vector has entered and expressed in the cells. AAV transduction ability was estimated using four scales of color intensity: detected color: bright: 1 point or +; bright, vivid color: 2 points or ++; strong color: 3 points or +++; and very bright color: 4 points or ++++. Table 11 shows exemplary RCTI scoring of AAV2 transduced retinas, and sequence numbers 129–132 in order of appearance. Table 12 shows exemplary RCTI scoring for AAV2 transduction in both human cells (HEK293 cells or ARPE19 cells) or mouse retina, and sequence numbers 129–132 in order of appearance.
[0172] [Table 11]
[0173] [Table 12]
[0174]
[0168] As shown in Figures 7-11 and Tables 10-12, the N54 peptide (LALGQTTKPA) can be inserted into VP1 of all AAV vectors to enhance propagation across the vector's internal limiting membrane (ILM) and expression in retinal cells. The VFGF-Trap protein was found to be most highly expressed in HEK293 cells induced by AAV6.N54-VEGF-trap, followed by AAV2.N54-VEGF-trap and AAV1.N54-VEGF-trap. In ARPE-19 cells, the VEGF-Trap protein was expressed similarly via both AAV2.N54-VEGF-trap and AAV6.N54-VEGF-trap.
[0175]
[0169] Figures 12-15 and Tables 12-16 show LCNV studies performed using mice transduced with wild-type AAV vectors or modified AAV vectors as described herein. Figure 12 shows an LCNV study in which the modified AAV was administered to the mice prior to LCNV. AAV1, AAV2, or AAV6 were modified by insertion of LALGQTTKPA (SEQ ID NO: 14) in the VP1 capsid and had aflibercept (VEGF-Trap) as the transgene for delivery to the mouse eye. Modified AAV1 (Group 5, AAV1.N54-Aflibercept) contained LALGQTTKPA (SEQ ID NO: 14) inserted after the S588 amino acid residue of the VP1 capsid. AAV2 (Group 3, AAV2.N54-Aflibercept) contained LALGQTTKPA (SEQ ID NO: 14) inserted after the N587 amino acid residue of the VP1 capsid. AAV6 (group 4, AAV6.N54-aflibercept) contains LALGQTTKPA (SEQ ID NO: 14) inserted after the S588 amino acid residue of the VP1 capsid. Figure 13A shows the area of choroidal neovascularization in the eye of the LCNV study. Δaflibercept was a sham control in which AAV containing disruption in the open reading frame was administered to the eye of mice. Compared to the medium group, all three modified AAV groups showed a significant reduction in the area of choroidal neovascularization in the eye (AAV6.N54-aflibercept, p<0.001; AAV1.N54-aflibercept, p<0.01; and AAV2.N54-aflibercept, p<0.05). Figure 13B shows that the group administered AAV6.N54-aflibercept continued to show a significant reduction in the area of choroidal neovascularization in the eye (AAV6.N54-aflibercept, p<0.05). Figure 14 shows aflibercept concentrations in ocular and serum samples obtained from LCNV study mice. Figure 15 shows fluorescein angiography (FA) analysis of the protective effect of retinal aflibercept against LCNV-induced retinal damage in mice. The correlation between aflibercept concentration in the ocular cup and retinal damage caused by laser treatment was inverse.As shown in Figures 3C, 3D, Table 13, and Table 14, the most significant reduction in LCNV area in the AAV6.N54-aflibercept group corresponds to an increase in VEGF-Trap mediated by its modified AAV6.
[0176] [Table 13]
[0177] [Table 14]
[0178]
[0170] Tables 15 and 16 show exemplary additional studies for determining the localization of AAV vectors and the expression of AAV vector cargo (e.g., aflibercept) after administration to the eye. The studies in Table 15 may be based at least in part on fundus imaging and IHC as described herein. The studies in Table 16 may be based at least in part on LCNV, FA, OCT, FP, histological examination, and IHC.
[0179] [Table 15]
[0180] [Table 16]
[0181] Example 8 In vivo study of AAV2.N54 capsid for intravitreous delivery in a weaned livestock pig model.
[0171] Intravitreal delivery of gene therapies for the treatment of eye diseases is a preferred method because it does not cause retinal detachment, can result in panretinal transduction, and can be performed under local anesthesia in an outpatient clinic. Wild-type AAV vectors do not adequately cross the internal limiting membrane (ILM) of the eye to transduce tissue. As such, modified AAV capsids with the ability to penetrate the ILM are required for the successful delivery of gene therapies to the intended target. Example 8 presents results of an engineered AAV2.N54 vector with the ability to deliver green fluorescent protein (GFP) deeply into eye tissue in a weaned livestock pig model.
[0182] Cloning and AAV vector production
[0172] The AAV2 wild-type capsid gene was used as a starting material to manipulate novel AAV variant capsids. Briefly, several peptide sequences were manipulated, reverse transcribed into optimized DNA sequences, and cloned to specific locations in the AAV2 wild-type capsid gene to produce AMI053, AMI054, AMI101, AMI104, and AMI105 plasmids. Recombinant baculovirus (rBV) was generated and used together with rBV-CMV-GFP to co-infect Sf9-V432-AG cells to produce AAV vectors expressing GFP. The AAV vectors were purified using two rounds of ultracentrifugation with a cesium chloride (CsCl) density gradient. CsCl was removed by two rounds of desalting on a PD-10 desalting column, and the mixture was formulated into formulation buffer.
[0183] Experimental Design
[0173] The animals were divided into six groups, and two animals were used per group for intravitreal injection of different AAV vectors according to Table 17.
[0184] [Table 17]
[0185] surgery
[0174] The test substances were prepared in a form ready for immediate injection and stored below -70°C until use. Thirty minutes before injection, each test substance was thawed, briefly centrifuged (1,000 rpm x 10 seconds) to collect the liquid at the bottom of the tube, and then heated in a 37°C water bath for 20 minutes, vortexed to reduce viral agglutination; each tube was shaken to condense the liquid at the bottom of the tube.
[0186]
[0175] The day before the surgery, the animals were fasted overnight before anesthesia administration. On the day of intravitreal injection, buprenorphine (0.01-0.05 mg / kg) was administered intramuscularly (IM) to each animal before the injection. Approximately 15 minutes before the anesthetic injection, the animals were given atropine (0.01-0.05 mg / kg, IM). Subsequently, the animals were anesthetized with ketamine / dexmedetomidine (IM) for injection, and the eyes were aseptically prepared using a topical 5% betadine solution, followed by rinsing with sterile saline, and one drop each of 0.5% propalacaine HCl and 10% phenylephrine HCl were applied. The conjunctiva was gently grasped with Colibri forceps, and the needle was pointed slightly posteriorly to avoid contact with the lens, and injected 2-3 mm posterior to the superior edge (through the ciliary body flattening) (27-30G needle). The injection was performed, and the needle was slowly withdrawn. After the injection procedure, one drop of antibiotic eye drops was applied topically to the surface of the eyeball. Subsequently, the animals were given atipamezole intramuscularly to reverse the effects of dexmedetomidine and recover normally from the surgery.
[0187] Observation from the side of the cage
[0176] With particular attention paid to both eyes, the animals were observed daily from the side of the cage for illness and death. No illnesses or deaths occurred during the course of this study.
[0188] Eye examination
[0177] Pupil dilation for ophthalmoscopic examination was performed using topical 1% tropicamide HCl (one drop in each eye 15 minutes prior to the examination). A complete ophthalmoscopic examination (modified Hackett and McDonald) using a slit-lamp biomicroscope and indirect ophthalmoscope to assess ocular surface morphology, anterior and posterior inflammation, cataract formation, and retinal changes was performed according to the experimental design described above. No ocular findings were observed during these assessments. All groups had a score of zero (0) at all time points assessed, indicating no findings.
[0189] Fundus imaging
[0178] On the day before the fundus imaging procedure on day 21, the animals were fasted overnight before anesthesia administration. On the day indicated in the study plan, the animals were anesthetized with ketamine / dexmedetomidine (IM) and imaged using Ret Cam 3 (Natus). First, color images were acquired, followed by cobalt blue images. Settings were kept constant across all groups. The acquisition settings were set for group 6 (V226) positive control animals.
[0190] result
[0179] No abnormal ocular findings were observed throughout the experiment. To ensure that all animals were in good condition according to the study protocol, pupillary dilation for ophthalmoscopic examination was performed using topical 1% tropicamide HCl (one drop in each eye 15 minutes prior to the examination). A complete ophthalmoscopic examination (modified Hackett and McDonald) using a slit-lamp biomicroscope and indirect ophthalmoscope to assess ocular surface morphology, anterior and posterior inflammation, cataract formation, and retinal changes was performed according to the experimental design table above. No ocular findings were observed during these assessments.
[0191] Demonstration of GFP expression in pig eye tissue
[0180] GFP expression was observed in the eyes of all six animal groups 21 days after intravitreal injection of different AAV vectors containing the GFP gene into the eyes of pigs, based on fundus imaging. However, as shown in fundus imaging, GFP expression levels were low in groups 1, 3, 4, and 5, while groups 2 and 6 had much higher GFP expression levels (Figure 16). Further examination of fundus images on a scoring scale showed that group 6 had the highest GFP expression, represented by a +++ score in both animals, followed by group 2 with five + scores and one single + score. Groups 1, 3, and 4 had similar expression levels with one + score. Group 5 had the lowest expression level (Table 18).
[0192] [Table 18]
[0193] IHC demonstration of deep penetration of AAV2-N54 vector into ocular tissue
[0181] Frozen sections (14 μm) were evaluated for the localization of GFP, RPE65, phalloidin, and DAPI in ocular tissue, and the results are shown in Figure 17. Merged images are shown on the left, and GFP channel pullouts are shown on the right. These results indicate that animals in group 2 (621 OS) injected with engineered AAV (named AAV2.N54) produced from AMI054 showed stronger and deeper GFP penetration in ocular tissue compared to control group 6 (628 OS) injected with AAV produced from V226. These results were further confirmed when frozen sections were examined in more detail using a scoring scale (Table 19). For the investigation of ocular GFP expression across all eyes registered for frozen section analysis, GFP expression was scored across all retinal layers and outer retinal layers; each eye is represented by a single row. Dark gray cells (+++) indicate the highest GFP expression; medium green cells (++) indicate moderate GFP expression; medium gray cells (+) indicate weak GFP expression; light gray cells (-) indicate no GFP expression. Abbreviations: GCL / ILM - Ganglion cell layer / internal limiting membrane; IPL - Inner plexiform layer; INL - Inner granular layer; OPL - Outer plexiform layer; ONL - Outer granular layer; IS - Inner segment; OS - Outer segment; RPE - Retinal pigment epithelium; C - Choroid; S - Sclera.
[0194] [Table 19]
[0195]
[0182] The frozen sections examined were initially examined under a standard microscope, and then the frozen sections of animals in group 2 (620 OD and 621 OD) were further examined under a confocal microscope. The results are shown in Figure 18. From these clear images, the inventors can confirm that GFP-expressing cells are widely distributed from the GCL layer to the RPE layer. This clearly demonstrates that the AAV2.N54 capsid can efficiently cross the ILM and penetrate deeply into the ocular tissue of pig eyes to the RPE layer.
[0196]
[0183] Figure 19A shows intravitreous delivery of AAV2.AMI054-GFP (modified AAV2 including LALGQTTKPA (SEQ ID NO: 14) insertion) to the eye of a pig. IHC staining showed GFP fluorescence in the retinal layer. Figure 19B shows GFP expression in each retinal layer of an eye administered with AAV2.AMI054-GFP. Confocal image number 122 of frozen section animal number 620-OD is aligned with published images of human retinal hematoxylin and eosin (H&E) staining methods. Results from the pig model study demonstrated that AAV2.N54-GFP, which has an N54 peptide (sequence LALGQTTKPA (SEQ ID NO: 14)) insertion at the C-terminal position N587 of AAV2.VP1, produces a very high delivery effect in GFP expression, exemplified by strong fluorescence and deep and broad distribution through the retinal layer and cells (Figure 19B). Strong and broad expression of GFP demonstrated that the AAV2.N54 capsid delivers the transgene to corresponding layers and cells in large animals and humans. Figure 20 shows a comparison of GFP expression in porcine retinas between eyes administered with AAV2.AMI054-GFP and eyes administered with AAV2.7M8-GFP (control). Retinas transduced with AAV2.AMI054-GFP showed GFP expression in all retinal layers, in contrast to retinas transduced with AAV2.7M8-GFP. GFP fluorescence in AAV2.AMI054-GFP transduced retinas was twice as strong as in AAV2.7M8-GFP transduced retinas. Table 20 shows the GFP expression intensity levels in human cells (HEK293 cells or ARPE19 cells), mouse models, and porcine models transduced with the five modified AAVs described herein: AMI053, AMI054, AMI101, AMI104, or AMI105. The increasing number of + signs indicates the increased GFL intensity detected in the transduced cells.
[0197] [Table 20]
[0198]
[0184] This study was conducted to evaluate the effect of six different AAV2 virus capsid variants on the GFP expression pattern after a single intravitreal injection in weaned domestic pigs (Hampshire crossbreed). Clinical laboratory tests showed no ocular findings at days 7 and 21. GFP was readily observed in vivo in all groups by cobalt blue fundus imaging. GFP expression was further evaluated in groups 1, 2, 3, 4, and 6 by cross-sectional analysis of frozen sections. Group 6 (V226; positive control) showed strong and broad GFP expression in both fundus imaging and cross-sectional analysis. The GFP signal was strongest from the GCL layer to the OPL layer, but less strong from the ONL layer to the RPE layer. Group 2 (AMI054) also showed strong and broad fundus expression of GFP, and strong expression in a total of seven layers, from the GCL layer to the OS layer. Mild differences in fundus imaging among groups 1 (AMI053), 3 (AMI101), and 4 (AMI104) were also evident in cross-sectional analysis, with 618 OD from group 1 exhibiting broad and bright expression throughout the outer plexiform layer (OPL). GFP expression in group 3 (AMI101) was bright in the ganglion cell layer and moderate throughout the remaining layers. In group 4, GFP expression was moderate to low throughout the retina. Very high expression was observed in the inner granular layer and outer plexiform layer for groups 1, 2, and 6. Morphological analysis of these GFP-positive cells revealed amacrine cell identity; future studies will utilize co-labeling approaches to assess whether amacrine markers coexist with GFP. Choroidal and scleral GFP expression was not observed in either eye, and RPE GFP expression was minimal compared to other retinal layers. In summary, group 2 (AAV2.N54) showed the broadest layer of GFP expression and, along with strong GFP expression, penetrated deeply through seven layers of ocular tissue, outperforming group 6 (V226).
[0199] Example 9 Evaluation of the in vivo distribution and transgene expression of AAV GFP candidates after intravitreous administration in non-human primates.
[0185] To evaluate the in vivo distribution and concentration of green fluorescent protein (GFP) expression of candidate AAVs after intravitreous (IVT) administration in African green monkeys. Monkeys undergo baseline screening to assess AAV neutralizing antibody (nAb) seronegativity, total blood count (CBC), general health issues, and eye health status by slit-lamp biomicroscopy, fundus examination, color fundus imaging, confocal scanning laser ophthalmoscopic examination (cSLO), and optical coherence tomography (OCT). nAb-negative monkeys with normal findings are enrolled in this study and assigned to the treatment group (Table 21). For baseline screening and all subsequent procedures, anesthesia is achieved using intramuscular ketamine (8 mg / kg) and xylazine (1.6 mg / kg) that can produce an effect, as well as pupillary dilation using local 10% phenylephrine, 1% tropicamide, and / or 1% cyclopentolate.
[0200] [Table 21]
[0201] Intravitreous (IVT) medication
[0186] Administer 0.5% topical propalacine and allow it to take effect for 30 seconds, then position the eyelid retractor, and subsequently rinse the surface of the eyeball with 5% betadine solution, followed by sterile 0.9% saline. Perform IVT injection in both eyes (OU) according to the procedure assignment (Table 21), using a 31 gauge 8 mm (5 / 16 inch) needle / syringe (Ulticare VetRx U-100 or equivalent), inserting it inferior temporally at the level of the serrated edge, approximately 2 mm posterior to the edge. Administer topical antibiotic ophthalmic ointment (neomycin, polymyxin, bacitracin, or equivalent) after injection.
[0202] Systemic immunosuppressive regimen
[0187] Animals were given intramuscular (IM) delivery of methylprednisolone (8 mg / kg) on day 1, and then once a week for three weeks (Table 22).
[0203] [Table 22]
[0204] Intraocular pressure measurement
[0188] At the specified time point (Table 22), measure the intraocular pressure (IOP) in both eyes (OU) using a TonoVet tonometer set to the canine (d) calibration setting. Take three measurements from each eye and calculate the mean IOP.
[0205] Slit-lamp examination
[0189] At the specified time point (Table 22), examine both eyes (OU) by slit-lamp biomicroscopic observation. Apply scoring using a non-human primate ophthalmic scoring system to quantify clinical ocular findings and derive a summary score from the examination items.
[0206] Fundus imaging
[0190] At the specified time point (Table 22), perform color anterior and fundus imaging for detecting GFP expression, as well as fluorescence fundus imaging, in both eyes (OU) using a Topcon TRC-50EX retinal camera together with Canon 6D digital imaging hardware and New Vision fundus image analysis system software, with additional marginal images obtained in each quadrant, for a 50° visual field centered on the macula. Take color fundus photographs at a shutter speed (Tv) of 1 / 25 s, ISO 400, and flash 18. Take monochromatic and color fluorescence images with the insertion of excitation and barrier filters (480 nm excitation / 525 nm barrier filter), Tv 1 / 5 s, ISO 3200, and flash 300. Evaluate fluorescence photographs using a scoring system to define the degree of GFP expression and apply quantitative analysis as needed (scores of 0 = none present; 1 = trace amount; 2 = little; 3 = moderate; 4 = bright; and 5 = strong in the fovea, periphery, and perivascular regions of the eye).
[0207] Optical coherence tomography (OCT) and confocal scanning laser ophthalmoscopy (cSLO)
[0191] At the designated time point (Table 22), perform OCT and cSLO OU using the Heidelberg Spectralis OCT HRA (or OCT Plus) with the AutoRescan tracking imaging function referring to the Heyex TruTrack and baseline images. Obtain cSLO infrared (IR) and autofluorescence (AF) retinal images using a wide-angle 50° lens, and then perform an overall OCT volume scan of the entire macula at a high-density scan interval. Quantitatively evaluate the images, if necessary, using quantitative analysis of OCT retinal thickness data and GFP expression. If permitted by pupil size and the transparency of the dioptric media, acquire peripheral fields using a wide-angle lens and / or use the composite image function to maximize the area of the retina captured in each image file.
[0208] Clinical observation
[0192] Check for general health problems twice a day by observing the animals from the side of the cage starting one week before dosing. Evaluate feed consumption and overall appetite by visual inspection of the feed dish and the cage floor before daily feeding and before cage cleaning. Evaluate the animals for signs of ocular inflammation, including swelling, discoloration, strabismus, or squinting.
[0209] Body weight
[0193] Measure the body weight of the animals at the designated time point (Table 22).
[0210] CBC blood profile with differential
[0194] At the designated time point (Table 22), collect 0.5 - 1 mL of whole blood and transfer it directly to a K3EDTA lavender-top tube for determination of the CBC blood profile with differential by a Hemavet analyzer.
[0211] Serum collection
[0195] Collect whole blood (3 mL) via the femoral vein or saphenous vein at the specified time points (Table 22). Transfer the blood to a Vacutainer tube (in the absence of anticoagulants), incubate at room temperature for approximately 1 hour, then centrifuge at 4000 rpm at 4°C for 10 minutes, and isolate serum aliquots (approximately 0.5 mL x 2 aliquots per time point). Store the aliquots below -70°C and transport them to the designated laboratory for nAb analysis.
[0212] end
[0196] After confirming the final image quality before the defined endpoint, the monkeys were sedated with ketamine (8 mg / kg) and xylazine (1.6 mg / kg) that could have an effect intramuscularly, and euthanized with pentobarbital sodium (100 mg / kg IV).
[0213] Eye collection
[0197] After placing a suture at the corneal margin at the 12 o'clock position, remove the eyeball and excise excess orbital tissue. Eye collection for hematoxylin and eosin (H&E) and immunohistochemistry (IHC) staining: After removing approximately 200 μL of vitreous humor, three eyes from groups 2-6 and one eye from group 1 are fixed by injecting approximately 400 μL of 4% paraformaldehyde (PFA) into the vitreous cavity, then immersed in 4% PFA at room temperature for 24 hours, then transferred to PBS containing 0.05% sodium azide, stored at 4°C in a Credo Cube temperature-controlled cryogenic container, and transported to the sponsor-designated laboratory for H&E and GFP IHC staining and analysis of at least 20 horizontal sections spanning the macular region of the posterior pole. The vitreous humor is stored below -70°C and transported to the sponsor for protein analysis by ELISA. Eye collection for protein and RNA analysis: One eye from each group is rapidly frozen in liquid nitrogen vapor before disassembling along the natural tissue plane at room temperature. The anterior portion is removed, then longitudinal sections are placed in the frozen eye cup, the frozen posterior pole is flat-mounted, and the vitreous humor is collected. The vitreous fluid (total volume approximately 2.5 mL) is divided into two aliquots. The flat mount is divided into upper and lower semi-flat mounts, and the retina is separated from the RPE / choroid and collected individually. All samples are placed in labeled cryogenic vials, stored below -70°C, and transported to the sponsor for protein analysis by GFP ELISA and mRNA analysis by RT-PCR. To minimize tissue cross-contamination, the instrument is cleaned between eyes and between tissues with water, and then with 70% isopropyl alcohol.
[0214] Data Analysis
[0198] Statistical Methods: The data derived from the evaluation items of the protocol definition listed in Table 22 are sorted, summarized, and analyzed as detailed in Table 23. Descriptive statistics are applied where appropriate, taking into account the sample size.
[0215] [Table 23]
[0216] Example 10
[0199] Efficacy study and long-term PK study of intravitreous AAV vector candidate in a non-human primate model of laser-induced choroidal neovascularization
[0200] Determination of long-term intraocular PK and efficacy evaluation of expressed genes of adeno-associated virus (AAV) vector candidates expressing aflibercept after intravitreal (IVT) administration in African green monkeys targeting exudative age-related macular degeneration (wAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and polypoid choroidal vasculopathy (PCV). Monkeys undergo baseline screening to assess AAV neutralizing antibody (nAb) seronegativity, complete blood count (CBC), general health problems, and eye health status by intraocular pressure measurement, slit-lamp biomicroscopy, fundus examination, color fundus photography, fluorescein angiography (FA), confocal scanning laser ophthalmoscopic examination (cSLO), and optical coherence tomography (OCT). nAb-negative monkeys with normal findings were enrolled in this study and assigned to treatment groups randomized by sex and baseline weight (Table 24). To accommodate the time required for imaging, the monkeys were divided into three cohorts for daily laser induction of CNV, medication, and imaging (Table 25). For baseline screening and all subsequent procedures, anesthesia was performed using intramuscular ketamine (8 mg / kg) and xylazine (1.6 mg / kg) that could be effective, and pupillary dilation was achieved using topical 10% phenylephrine, 1% tropicamide, and / or 1% cyclopentolate.
[0217] [Table 24]
[0218] [Table 25-1]
[0219]
Table 25-2
[0220] Systemic immunosuppressive regimen
[0201] - From day 1 and for an additional 4 weeks, intramuscular (IM) delivery of methylprednisolone (8 mg / day) once weekly (Table 25).
[0221] Intravitreal administration
[0202] Administer topical proparacaine 0.5%, place an eyelid speculum, and then rinse the ocular surface with 5% betadine solution followed by sterile 0.9% saline. Perform IVT injection in both eyes (OU) according to the treatment assignment (Table 24), inserting a 31-gauge 8 mm (5 / 16 inch) needle approximately 2 mm posterior to the limbus at the level of the锯齿缘(原文此处有误,可能是“ora serrata”) inferiorly. After injection, administer topical antibiotic eye ointment (neomycin, polymyxin, bacitracin, or equivalent).
[0222] Laser induction of CNV
[0203] Perform laser photocoagulation at the designated time points (Table 25). Achieve mydriasis before laser treatment using topical 10% phenylephrine hydrochloride and 1% cyclopentolate eye drops. Apply topical administration of 1% atropine gelled eye drops additionally 1 or 2 nights before laser treatment to enhance mydriasis. The ophthalmologist uses an Iridex Oculight TX 532 nm laser with a laser duration of 100 ms, a spot size of 50 μm, and an output of 750 mW, such that 6 laser spots are symmetrically placed within the perimacular region of each eye. Perform color fundus photography immediately after laser treatment to document the laser lesions. Any spot showing severe retinal / subretinal hemorrhage immediately after laser and not resolved by the time of follow-up examination is excluded from the analysis.
[0223] Intraocular pressure examination
[0204] At the specified time points (Table 25), intraocular pressure (IOP) measurements are performed using a TonoVet (iCare, Finland) tonometer set to the canine (d) calibration setting. Three measurements are taken from each eye at each time point, and the average IOP is determined.
[0224] Slit-lamp biomicroscope observation
[0205] At the specified time (Table 25), intraocular inflammation is examined using slit-lamp biomicroscopy. A scoring system using a non-human primate ophthalmic examination scoring system is applied to quantify clinical ophthalmic findings and derive a summary score from the examination items.
[0225] Color fundus photography and fluorescein angiography
[0206] At the specified time (Table 25), bilateral color fundus images are acquired using a Topcon TRC-50EX retinal camera with Canon 6D digital imaging hardware and New Vision fundus image analysis system software, covering a 50° field of view centered on the orbit. Fluorescein angiography (FA) is performed with intravenous administration of 0.1 mL / kg of 10% fluorescein sodium. To allow fluorescein flushing between angiography series, OD FA is performed at least 2 hours prior to OS angiography. Fluorescein leakage in angiography of CNV lesions is graded (I-IV; Table 26) by evaluating the composite image created after uniform adjustment of image intensity. Image fluorescence density analysis of the later raw angiography is also performed using ImageJ software.
[0226] [Table 26]
[0227] Optical coherence tomography
[0207] At the specified time points (Table 25), OCT is performed using Heidelberg Spectralis OCT Plus with eye-tracking and HEYEX image capture and analysis software. A full volume scan encompassing the posterior retina is performed. At the pre-laser examination time point, a retinal thickness map and cross-sectional display images are acquired. At the post-laser examination time point, a full volume scan of the entire macula is performed, encompassing six star-shaped scans per eye centered on each lesion, in addition to six laser spots at high-density scan intervals. The principal axis of maximum CNV complex formation within each star-shaped scan at each laser lesion is defined, and the CNV complex area is measured using the freehand tool in ImageJ to depict the CNV complex boundary, in square microns (μm). 2 Calculate the maximum composite area in ).
[0228] Clinical observation
[0208] General health issues should be checked twice a week by observing the side of the cage, starting one week before medication is administered. Overall appetite should be assessed by visually inspecting the individual animal's daily feed consumption after daily feeding, or the cage floor before cage cleaning. During these observations, the animal should be observed for signs of eye inflammation, paying particular attention to symptoms such as strabismus or eye rubbing.
[0229] body weight
[0209] Weight will be collected at the specified time (Table 25).
[0230]
[0210] Serum collection
[0211] As previously detailed, whole blood (4 mL) is collected via the femoral or saphenous vein at the specified time points (Table 24) while the animals are kept sedated. The blood is transferred to a Vacutainer tube (in the absence of anticoagulants) and incubated at room temperature for approximately 1 hour, then centrifuged at 4000 rpm at 4°C for 10 minutes, and serum aliquots (approximately 0.75 mL x 2 aliquots per time point) are isolated. The aliquots are stored below -70°C and transported to the sponsor-designated laboratory for nAb analysis.
[0231]
[0212] Collection of aqueous humor and vitreous fluid
[0213] Aqueous humor (50 μL each and approximately 150 μL total at the end of the study) is sampled at the specified time points (Table 25) after sterile preparation of the eye, as for IVT injection, using a 0.3 mL insulin syringe with a 31 gauge needle. Vitreous fluid (50 μL each and approximately 150 μL at the end of the study) is sampled at the specified time points (Table 25) after sterile preparation of the eye, as for IVT injection, using a 0.5 mL insulin syringe with a 28 gauge needle. After bilateral aqueous humor and / or vitreous puncture (except at the end of the study), an ophthalmic ointment (or equivalent) of the three topical antibiotics neomycin, polymyxin, and bacitracin is administered. The aqueous humor and vitreous samples are transferred to pre-labeled cryotubes, placed on wet ice, and stored at below -70°C within 30 minutes of collection.
[0232]
[0214] End
[0215] After checking the image quality before the final destination, the animals are euthanized with pentobarbital sodium (100 mg / kg IV, which may produce an effect).
[0233]
[0216] Eye Collection
[0217] Remove the eyeball and excise excess orbital tissue. Eye collection for flat-mount immunohistochemistry (IHC) staining and imaging analysis: Inject approximately 200 ml of 4% paraformaldehyde (PFA) into three pairs of eyes from each group, then post-fix in PFA for 6 hours, store at 4°C in a Credo Cube temperature-controlled cryogenic container, and transport to the sponsor-designated laboratory for further processing. Remove the anterior portion by circumferential cutting at the level of the serrated edge, then make longitudinal sections in the optic cup to allow flat mounting for IHC and confocal imaging. Eye collection for protein analysis: Rapidly freeze three pairs of eyes from each group in liquid nitrogen vapor before disassembling along the natural tissue plane at room temperature. Remove the anterior portion, then place the longitudinal sections in the frozen optic cup, flat-mount the frozen post-polar, and collect the vitreous humor. Divide the vitreous fluid (total volume approximately 2.5 mL) into two aliquots. The retina is separated from the RPE / choroid, and each is collected individually.
[0234] Data Analysis The data resulting from the evaluation items of the protocol definition listed in Table 25 are sorted, summarized, and analyzed as detailed in Table 27. If the data meets the required assumptions, the specified statistical analysis is performed. If the data cannot meet the assumptions for the defined statistical method, alternative methods may be used, if possible. A p-value ≤ 0.05 is considered statistically significant.
[0235] [Table 27]
[0236]
[0218] Preferred embodiments of the present invention are shown and described herein, but it will be apparent to those skilled in the art that such embodiments are provided only as examples. Numerous variations, alterations, and substitutions will now come to mind to those skilled in the art without departing from the present invention. It should be understood that various substitutes for the embodiments of the present invention described herein may be used in carrying out the present invention. The following claims are intended to define the scope of the present invention, and that the methods and structures and their equivalents within the scope of these claims are covered thereby.
Claims
1. (a) L-A-L-G-X3-X1-X1-X4 (SEQ ID NO: 94), (b) L-K-L-G-X3-X1-X1-X4 (SEQ ID NO: 95), or (c) V-K-L-G-X3-X1-X1-X4 (SEQ ID NO: 96) 1. An AAV capsid comprising a polypeptide sequence of: X1 is alanine (A), asparagine (N), glutamine (Q), serine (S), threonine (T), glutamic acid (E), aspartic acid (D), lysine (K), arginine (R), or histidine (H); X3 is E, S, or Q; X4 is K, R, E, or A; An AAV capsid, wherein the polypeptide sequence is present in the VP domain of the AAV capsid.
2. The polypeptide sequence is (a), wherein (a) is (i) L-A-L-G-X3-X1-T-X4 (SEQ ID NO: 99) or (ii) L-A-L-G-X3-X1-S-X4 (SEQ ID NO: 100) The AAV capsid of claim 1 .
3. The polypeptide sequence is (i), a) L-A-L-G-X3-X1-T-R (SEQ ID NO: 101); b) L-A-L-G-X3-X1-T-K (SEQ ID NO: 102); c) L-A-L-G-X3-X1-T-E (SEQ ID NO: 103); or d) L-A-L-G-X3-X1-T-A (SEQ ID NO: 104) The AAV capsid of claim 2,
4. 3. The AAV capsid of claim 2, wherein the polypeptide sequence is (ii), and (ii) is L-A-L-G-X3-X1-SK (SEQ ID NO: 105).
5. The polypeptide sequence is (b), (i) L-K-L-G-X3-X1-T-X4 (SEQ ID NO: 106) The AAV capsid of claim 1 .
6. The AAV capsid of claim 5, wherein (i) is L-K-L-G-X3-X1-T-K (SEQ ID NO: 107).
7. The polypeptide sequence is (c), (i) V-K-L-G-X3-X1-T-X4 (SEQ ID NO: 97) or (ii) V-K-L-G-X3-X1-X1-K (SEQ ID NO: 98) The AAV capsid of claim 1 .
8. The AAV capsid of any one of claims 1 to 7, wherein the serotype of the AAV capsid is selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, and AAV13.
9. The AAV capsid of any one of claims 1 to 7, which is a chimeric AAV capsid comprising amino acid sequences from two or more serotypes selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, and AAV13.
10. The AAV capsid of any one of claims 1 to 9, which is an AAV serotype 2 or a chimeric AAV capsid comprising an amino acid sequence derived from an AAV serotype 2.
11. The AAV capsid of any one of claims 1 to 10, comprising an amino acid sequence having at least about 60% identity to any one of SEQ ID NOs: 28 to 47.
12. The AAV capsid of any one of claims 1 to 11, wherein the polypeptide sequence is in the GH loop or loop IV of the AAV capsid.
13. The polypeptide sequence is (i) within amino acids 570-611 of AAV2; (ii) within amino acids 571-612 of AAV1; (iii) within amino acids 560-601 of AAV5; (iv) within amino acids 571-612 of AAV6; (v) within amino acids 572-613 of AAV7; (vi) within amino acids 573-614 of AAV8; (vii) within amino acids 571-612 of AAV9; or (viii) within amino acids 573 to 614 of AAV10 The AAV capsid of any one of claims 1 to 12, wherein the insertion is
14. 14. The AAV capsid of any one of claims 1 to 13, wherein the polypeptide sequence is an insertion at positions 452, 453, 466, 467, 468, 471, 585, 586, 587, and / or 588 of SEQ ID NO:
1.
15. The AAV capsid of any one of claims 1 to 14, further comprising at least one amino acid mutation relative to a wild-type AAV capsid.
16. The AAV capsid of claim 15, wherein at least one amino acid mutation is at positions 452, 453, 466, 467, 468, 471, 585, 586, 587, and / or 588 of SEQ ID NO:
1.
17. 17. The AAV capsid of claim 16, wherein at least one amino acid mutation is an R to A mutation at amino acid position 585 or 588 of SEQ ID NO:
1.
18. A vector comprising a polynucleotide sequence encoding the AAV capsid of any one of claims 1 to 17.
19. 19. The vector of claim 18, wherein the AAV capsid is of serotype AAV2 or a chimeric AAV capsid comprising an amino acid sequence derived from serotype AAV2.
20. 20. The vector of claim 18 or 19, comprising a polynucleotide sequence encoding a transgene.
